EX-10.1





 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
 Exhibit 10.1 

MANUFACTURING AND SUPPLY AGREEMENT 

(the “Agreement”) 

effective as of 1st January, 2019 

(the “Effective Date”), 

by and between 
 NOVARTIS
PHARMA AG 
 Lichtstrasse 35 

CH-4056 Basel, Switzerland 

(“NOVARTIS”) 

and 
 RECRO GAINESVILLE LLC

 1300 Gould Drive 

Gainesville, GA 30504 

(“SUPPLIER”) 
 EXECUTION VERSION













 TABLE OF CONTENTS 

 

							
	 1.
	 	 DEFINITIONS AND INTERPRETATIONS
	  	 	4	 
			
	 2.
	 	 SCOPE OF THE AGREEMENT
	  	 	9	 
			
	 3.
	 	 PRE-APPROVAL, VALIDATION AND CAPACITY
	  	 	12	 
			
	 4.
	 	 COMPONENTS AND TOLLING MATERIALS
	  	 	12	 
			
	 5.
	 	 FORECASTING, ORDERS AND DELIVERY
	  	 	15	 
			
	 6.
	 	 PRICE AND PAYMENT TERMS
	  	 	18	 
			
	 7.
	 	 QUALITY ASSURANCE
	  	 	19	 
			
	 8.
	 	 CHANGES TO PRODUCTS
	  	 	20	 
			
	 9.
	 	 EXCHANGE OF INFORMATION
	  	 	20	 
			
	 10.
	 	 DEFECTIVE PRODUCT
	  	 	20	 
			
	 11.
	 	 CONTINUOUS IMPROVEMENT, KPI, RELATIONSHIP MANAGEMENT
	  	 	21	 
			
	 12.
	 	 RESPONSIBLE PROCUREMENT
	  	 	22	 
			
	 13.
	 	 HSE, RISK MANAGEMENT AND BUSINESS CONTINUITY
	  	 	23	 
			
	 14.
	 	 PRODUCT RECALLS AND RETURNS
	  	 	24	 
			
	 15.
	 	 INTELLECTUAL PROPERTY
	  	 	24	 
			
	 16.
	 	 INDEMNIFICATION AND LIABILITIES
	  	 	27	 
			
	 17.
	 	 INSURANCE
	  	 	28	 
			
	 18.
	 	 CONFIDENTIALITY
	  	 	29	 
			
	 19.
	 	 TERM AND TERMINATION FOR CONVENIENCE
	  	 	30	 
			
	 20.
	 	 EXTRAORDINARY TERMINATION
	  	 	30	 
			
	 21.
	 	 EFFECTS OF TERMINATION OR EXPIRATION
	  	 	31	 
			
	 22.
	 	 GOVERNING LAW AND JURISDICTION
	  	 	32	 
			
	 23.
	 	 MISCELLANEOUS
	  	 	33	 


  

			
	EXECUTION VERSION	  	Page 2 of 54














 LIST OF ANNEXES 

 

			
	 ANNEX 1
	  	 Product & Pricing

		
	 ANNEX 2
	  	 Safety Stock Requirements

		
	 ANNEX 3
	  	 KPIs

		
	 ANNEX 4
	  	 Relationship Management

		
	 ANNEX 5
	  	 Trading Services Procedure

		
	 ANNEX 6
	  	 Quality Agreement

		
	 ANNEX 7
	  	 Additional HSE Requirements

		
	 ANNEX 8
	  	 Toll Materials Yield Loss Rates, Reimbursement Value and Inventory Count

		
	 ANNEX 9
	  	 Alkermes Patent Rights

		
	 ANNEX 10
	  	 Recro Patent Rights

		
	 ANNEX 11
	  	 List of Open Orders



  

			
	EXECUTION VERSION	  	Page 3 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

WHEREAS: 
  

	(A)	 NOVARTIS is engaged in the manufacture, marketing and sales of pharmaceutical products.



  

	(B)	 SUPPLIER is a company engaged in the processing and supply of pharmaceutical products holding the
necessary manufacturing licenses and permits in this respect. 


  

	(C)	 NOVARTIS and SUPPLIER are parties to that certain License and Supply Agreement dated as of [***] (as
amended through the date hereof, the “License and Supply Agreement”), and Novartis Pharmaceuticals Corporation and SUPPLIER are parties to that certain Development, License and Supply Agreement dated as of [***] (as amended through
the date hereof, the “Development, License and Supply Agreement”), pursuant to which agreements SUPPLIER performs certain services related to the processing and supply of certain pharmaceutical products to and for NOVARTIS
and Novartis Pharmaceuticals Corporation, respectively. 


  

	(D)	 NOVARTIS, Novartis Pharmaceuticals Corporation and SUPPLIER desire to terminate the Development, License
and Supply Agreement and the License and Supply Agreement (together, the “Original Agreements”) in all respects as of the Effective Date. 


  

	(E)	 NOVARTIS and SUPPLIER desire to amend and restate the terms pursuant to which SUPPLIER shall perform
certain services related to the processing and supply of the Products (as defined herein) pursuant to the Specifications and the terms and conditions of this Agreement and SUPPLIER confirms being able to properly perform such activities.



 IT IS AGREED AS FOLLOWS: 
  

	1.	 DEFINITIONS AND INTERPRETATIONS 



 

	1.1	 Defined Terms 



The following terms shall, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of such
terms shall have corresponding meanings: 
 “Affiliate” means any corporation or other business entity which, directly or
indirectly, is controlled by, controls, or is under common control with NOVARTIS or SUPPLIER, as the case may be. For such purposes, “Control” shall mean the direct or indirect ownership of at least fifty percent (50%) of the voting
interest in such corporation or other entity or the power in fact to control the management directions of such entity. 

“Alkermes” means Alkermes Pharma Ireland Ltd. 

“Alkermes Patent Rights” means all patents and patent applications listed in ANNEX 9 to which SUPPLIER holds an exclusive
sub-licensable license under that certain Asset Transfer and License Agreement between Alkermes and SUPPLIER dated 10 April 2015. 

“Annual KPI Compliance Review” means a meeting between the parties to discuss and review SUPPLIER’s level of
performance of the KPIs. 
 “API” means the active pharmaceutical ingredient(s) DexMethylphenidate HCL and Methylphenidate
HCL, as referenced in the Quality Agreement and the Specifications. 

  

			
	EXECUTION VERSION	  	Page 4 of 54














 “Apparent Defect” means any Defect which is visible or easily detectible
through routine incoming quality control measures. 
 “Applicable Standards” means all applicable cGxP as well as all laws,
regulations, guidelines, standards, permits and authorizations, including without limitation those listed in the Quality Agreement and those governing health, safety and environmental protection, applicable in the country where the Facility is
located and in each country of the Territory. 
 “Approved Subcontractor(s)” means any Affiliate of SUPPLIER or any other
third party (including suppliers of API and (Critical) Components) to which SUPPLIER has subcontracted in whole or in part its obligations hereunder in accordance with the terms set out herein and the Quality Agreement. Approved Subcontractors shall
be referenced in the Quality Agreement. 
 “Batch” means a defined quantity of Components and API, processed in one process
or series of processes, so that it could be expected to be homogeneous. 
 “Bridging Stock” has the meaning in Clause
21.3. 
 “Business Continuity Management” has the meaning in Clause 13.3. 

“Business Continuity Plan” has the meaning in Clause 13.3. 

“cGxP” means the current good manufacturing, distribution and storage practices specified by the US Code of Federal
Regulations, the EU, PIC, ICH and WHO guidelines and the corresponding national laws and regulations applicable in the country where the Facility is located and in each country of the Territory. In case of conflict, SUPPLIER shall be required to
comply with the stricter standard. 
 “Claims” means all third party demands, claims, actions, proceedings and liability
(whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever. 

“Components” means, collectively, all raw materials, excipients and any other materials (including, to the extent procured by
SUPPLIER, the API) required to Manufacture the Product in accordance with the Specifications. 
 “Confidential
Information” has the meaning in Clause 18.1.  
 “Confirmed Delivery Date” has the meaning in
Clause 5.2. 
 “Confirmed Order” has the meaning in Clause 5.2. 

“Confirmed Order Quantities” has the meaning in Clause 5.2. 

“Contract Year” means any twelve (12) month period beginning on January
1st, of each calendar year, provided, however, that the first Contract Year of this Agreement shall commence on the Effective Date and shall expire on December 31st of the same calendar year. 
 “Controlled Substance(s)” shall have the
meaning ascribed to such term in the Controlled Substances Act (21 U.S.C. § 801-904), as may be amended from time to time, and/or its equivalent in the other countries of the Territory. 

“Critical Components” means those Components listed as materials in the Quality Agreement. 

  

			
	EXECUTION VERSION	  	Page 5 of 54














 “Defective Product” means Product that: (i) was not
Manufactured, prepared, handled and/or shipped in compliance with applicable cGxPs, Applicable Standards, the Quality Agreement, master batch records and/or any other procedures or documents agreed upon by the parties in writing; (ii) does not
conform to the Specifications or any other Product related warranties or representations set out in this Agreement; (iii) has less than the Residual Shelf Life; (iv) is adulterated within the meaning of the U.S. Food, Drug, and Cosmetic
Act or similar provisions under Applicable Standards; and/or (v) is considered to contain a defect as determined under governing law and Applicable Standards in the Territory. “Defect” shall be interpreted accordingly. For the
avoidance of doubt, any Product that NOVARTIS is entitled to reject pursuant to the Quality Agreement shall be regarded as Defective Product for the purpose of this Agreement. 

“Deliver” or “Delivery” means the delivery of the Product by SUPPLIER pursuant to Clause
5.3. 
 “Development, License and Supply Agreement” has the meaning given in the preamble of this Agreement. 

“Equipment” means any equipment and machinery required in the Manufacture of the Product at the Facility. 

“Facility(-ies)” means SUPPLIER’s or its Approved Subcontractor’s
Manufacturing facility(-ies), located at: 1300 Gould Drive, Gainesville, GA 30504, USA and such other facilities as may be approved in writing by NOVARTIS from time to time in accordance with this Agreement
and the Quality Agreement. 
 “Forecast” has the meaning in Clause 5.1. 

“HSE” is the abbreviation for “health, safety and environmental protection”. 

“HSE Requirements” has the meaning in Clause 13.1. 

“Indemnitee” and “Indemnitor” have the meanings in Clause 16.3. 

“Initial Term” has the meaning in Clause 19.2. 

“Intellectual Property” means patents, trade secrets, Know-How, confidential or
proprietary information, technical data, trademarks, service marks, design rights, copyright or any other intellectual property right which may subsist anywhere in the world, whether capable of grant, registration or not. 

“Joint Supply Team” has the meaning in ANNEX 4. 

“Know-How” means all technical information,
know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to
compounds, formulations, compositions, products or to their manufacture, development, registration, use or commercialization or methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions
incorporating or comprising them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions,
processes, formulae, expertise and information, regulatory filings and copies thereof, relevant to the development, manufacture, use or commercialization of and/or which may be useful in studying, testing, development, production or formulation of
products, or intermediates for the synthesis thereof. 

  

			
	EXECUTION VERSION	  	Page 6 of 54














 “KPI” means the key performance indicators set out in ANNEX 3,
Part A and against which the performance by SUPPLIER under this Agreement will be measured and monitored by NOVARTIS. 

“Laboratory” has the meaning in Clause 23.3(a). 

“Latent Defect” means any Defect other than Apparent Defects. 

“License and Supply Agreement” has the meaning given in the preamble of this Agreement. 

“Manufacture” or “Manufacturing” means, as applicable, any and all operations, including without
limitation receipt of materials, processing, testing, sterilization, quality control, releasing, storing, sample retention, serialization and packaging for shipment, carried out by or on behalf of SUPPLIER in the preparation and supply of the
Products under this Agreement and the Quality Agreement. 
 “Manufacturing License(s)” means all licenses, permits,
approvals, authorizations and consents necessary for, or required in connection with, the lawful Manufacture of the relevant Products at the Facility for use, exportation, importation, distribution, marketing, promotion, sale and placement of the
Products in the Territory. 
 “Minimum Capacity” has the meaning in Clause 3.1. 

“Novartis Material” means Novartis New Material and Novartis Original Material. 

“Novartis New Material” means all information, documents and materials that are or will be generated by SUPPLIER, any Approved
Subcontractor or NOVARTIS under this Agreement, including without limitation, manufacturing and quality control instructions or requirements under any quality control agreements between the parties (including the Quality Agreement), and
specifications necessary to manufacture, label, package, store, handle, stability test, quality control test and release the Product, all in accordance with this Agreement, including without limitation the Product and partially-Manufactured Product.

 “Novartis Original Material” means all information, documents and materials that are, will be or have been provided by
NOVARTIS to SUPPLIER under this Agreement, including without limitation, Confidential Information and, where applicable, the API. 

“Order(s)” has the meaning in Clause 5.2(a). 

“Order Lead Time” has the meaning in Clause 5.2(a). 

“Original Agreements” has the meaning given in the preamble of this Agreement. 

“Patent Rights” means all patents and patent applications, including all divisionals, continuations, substitutions, re-examinations, reissues, additions, renewals, extensions, registrations, supplemental protection certificates, utility models, design patents and the like of any of the foregoing. 

“Price” means the price per unit of Product, as further defined in Clause 6.1 and ANNEX 1.
 
 “Product Marks” has the meaning in Clause 15.6. 

“Products” means the products listed in ANNEX 1 (as further specified in the Quality Agreement) conforming to the
Specifications, the Manufacturing and supply of which is the subject matter of this Agreement. 

  

			
	EXECUTION VERSION	  	Page 7 of 54














 “Quality Agreement” means that applicable version of the quality
agreement between the parties in relation to the Product and its Manufacturing, including, without limitation by way of a master agreement between SUPPLIER and/or its Affiliate(s) and a NOVARTIS Affiliate, a copy of which is attached hereto as
ANNEX 7. 
 “Quality Assurance” or “QA” means the sum total of the quality assurance arrangements
made with the purpose of ensuring that the Product meets the Specifications and is of the quality required for its intended use and shall specifically include all terms and activities as set forth in the applicable version of the Quality Agreement.

 “Recro Patent Rights” means all patents and patent applications listed in ANNEX 10. 

“Registration” means any and all governmental or Regulatory Authority approvals necessary or required for the Manufacture,
import, marketing, distribution and sale of the Product or the finished product comprised of the Product (as applicable) as labeled, packaged and presented for sale to the pharmaceutical trade, and the term “Registration” shall also apply
to any renewals of such approvals and to any other steps required to maintain such approvals. 
 “Regulatory Authority”
means any international, national or other governmental, regulatory or administrative authority or other body competent to grant, maintain and extend approvals, registrations or other consents for the Manufacturing, importation, marketing,
distribution or sale of pharmaceutical products and APIs, including without limitation the Products. 
 “Renewal Term” has
the meaning in Clause 19.2. 
 “Representatives” has the meaning in Clause 18.1. 

“Requested Delivery Date(s)” has the meaning in Clause 5.2(a). 

“Requested Order Quantities” has the meaning in Clause 5.2(a). 

“Residual Shelf Life” has the meaning in Clause 5.5. 

“Risk Management” has the meaning in Clause 13.3. 

“SEC” has the meaning in Clause 18.2. 

“Specifications” means the specifications for the Products, the API or Critical Components (as the case may be) as further
defined and referenced in the Quality Agreement and which may be amended only upon the mutual written agreement of the parties. 

“Supply Failure” has the meaning in Clause 5.8. 

“Term” has the meaning in Clause 19.2. 

“Territory” means all countries of the world except Canada. 

“Third Party Infringement” has the meaning in Clause 15.5(a). 

“Toll Material(s)” means any API as listed in ANNEX 8 and supplied by NOVARTIS to SUPPLIER free of charge for the
purpose of SUPPLIER Manufacturing and supplying the Product to NOVARTIS under this Agreement. 
 “Toll Materials Reimbursement
Value” is set forth in ANNEX 8.  
 “TSP” means the Trading Service Procedure as attached hereto as ANNEX
5. 

  

			
	EXECUTION VERSION	  	Page 8 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

“Validation” or “Validate” means (either collectively or separately, as applicable) (i) the successful
completion of all qualification activities in relation to the Facility and the Equipment; (ii) the successful validation of the analytical testing methods for the Product; and (iii) the successful Manufacture, at commercial scale, of [***]
validation Batches for the Product meeting predetermined validation acceptance criteria, normal Product release criteria and stability requirements as set forth in the Specifications and in a written validation plan to be mutually agreed by the
parties. 
  

	1.2	 Currency. Unless otherwise indicated, all monetary amounts are expressed in this Agreement in US Dollars
(“USD”). 


  

	1.3	 Interpretation. In this agreement unless otherwise specified: 



 

	 	(a)	 the division of this Agreement into clauses, sub-clauses and Annexes
and the insertion of headings are for convenience of reference only and shall not affect the interpretation of this Agreement; 


  

	 	(b)	 any reference in this Agreement to a clause or an annex refers to the specified Clause or Annex to this
Agreement; 


  

	 	(c)	 the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar
expressions refer to this Agreement; 


  

	 	(d)	 a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute
or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted; 



 

	 	(e)	 all references to the singaular shall include the plural and vice versa; 



 

	 	(f)	 the term “including” shall mean “including without limitation”; and 



 

	 	(g)	 any reference in this Agreement to a “day” or “week” shall be references to a calendar day
or week. Where express reference is made to “business day(s)” any such reference shall mean a day (with the exception of Saturday and Sunday) on which banks are open in Switzerland and New York, New York (USA). 



 

	2.	 SCOPE OF THE AGREEMENT 



 

	2.1	 Manufacturing and Supply. During the Term, SUPPLIER shall sell, Manufacture and Deliver the
Products to NOVARTIS and its Affiliates in accordance with the terms of this Agreement. The parties acknowledge that NOVARTIS prioritizes consistent high quality and timely supply of the Products to meet patient demand and that supply disruptions
may result in irreparable harm to NOVARTIS. To that end, SUPPLIER agrees to act in good faith in performing its obligations under this Agreement and shall not willfully delay Manufacturing nor withhold Delivery of the Products.



  

	2.2	 Exclusivity. [***] SUPPLIER shall produce and supply the Products exclusively for, and to, NOVARTIS.
[***] SUPPLIER shall supply to NOVARTIS its entire requirements of the Products and NOVARTIS will purchase its entire requirements of the Products exclusively from SUPPLIER, all subject to the following:  



 

	 	a)	 [***] NOVARTIS shall purchase all of NOVARTIS’ volume requirements for the Products from SUPPLIER and
SUPPLIER shall Manufacture, Deliver and supply all of NOVARTIS’ volume requirements for the Products. This exclusivity shall be solely for the Products as listed in 



  

			
	EXECUTION VERSION	  	Page 9 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

	 	ANNEX 1 and shall not extend to [***]; and 

  

	 	b)	 Notwithstanding anything to the contrary in this Agreement, the exclusivity obligation pursuant to this
Clause 2.2 shall cease to apply and NOVARTIS shall be free to purchase any of its requirements for the Product(s) from a different third party source or from a site of NOVARTIS (or a site of any NOVARTIS Affiliate) in the event that:



  

	 	(i)	 SUPPLIER is not able to (or it can reasonably be anticipated that SUPPLIER will not be able to) and/or fails to
supply for [***]; and/or 


  

	 	(ii)	 SUPPLIER is (or it can reasonably be anticipated that SUPPLIER will) be the subject of any insolvency,
bankruptcy or liquidation proceedings or the appointment of a receiver, custodian or trustee or any similar proceeding or appointment under applicable law. 



For the avoidance of doubt, the exclusivity pursuant to this Clause 2.2 shall be limited to commercial manufacturing activities and
shall not prevent NOVARTIS from performing any activities in relation to the preparation of a transfer of the Products to another manufacturing site or to the qualification or registration of such other manufacturing site, including without
limitation any supply qualification, regulatory registration and manufacturing, testing and validation activities. The parties’ obligations under this Clause 2.2 [***]. 

 

	2.3	 Supplier Warranty. SUPPLIER represents and warrants that it shall Manufacture, store, test release,
Deliver and supply the Product in compliance with: (i) the Specifications; (ii) cGxP; (iii) the Quality Agreement; (iv) the Manufacturing License(s); (vi) all Applicable Standards, including those governing health, safety and
environmental protection and those governing Controlled Substances, and that at Delivery the Product will be free from (vii) any security interest, claims, demands, liens and other encumbrances of any kind or character; and (viii) any
Defects. The parties agree that subject to the notification timelines set forth in Clause 10, the warranty set forth in this Clause 2.3 shall remain in full force and effect for the entire Residual Shelf Life of the Products.



  

	2.4	 Subcontractors. SUPPLIER shall not subcontract or delegate any portion of its obligations
hereunder except to an Approved Subcontractor. SUPPLIER shall ensure that any Approved Subcontractor performs its obligations pursuant to the terms of this Agreement, including the Quality Agreement and the HSE Requirements. Notwithstanding the
foregoing, SUPPLIER shall remain solely and fully liable for the performance of any Approved Subcontractor or supplier and shall remain exclusively responsible for all costs associated with any such subcontract or supply relationship.



  

	2.5	 Facility. SUPPLIER will Manufacture the Products exclusively at the Facility. Transfer of the
Manufacturing of the Products to another facility requires the prior written approval of NOVARTIS. SUPPLIER shall, at its own expense, provide and maintain all labor, plant, Equipment and services necessary to enable SUPPLIER to fulfil all its
obligations under this Agreement, including the Manufacturing of the Products. 



  

			
	EXECUTION VERSION	  	Page 10 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	2.6	 Novartis Material. All Novartis Material, whether or not patentable, shall be the sole and
exclusive property of NOVARTIS. SUPPLIER shall supply all Novartis New Material to NOVARTIS or its designee in accordance with the terms of this Agreement. SUPPLIER shall not sell or otherwise dispose of any Novartis Materials except as expressly
authorized by NOVARTIS, provided that to the extent NOVARTIS requests that SUPPLIER dispose of or destroy any Novartis Material, (i) such disposal or destruction shall be required to occur within [***] of NOVARTIS’ authorization of same in
accordance with the terms of the Quality Agreement; and (ii) [***]. SUPPLIER hereby grants to NOVARTIS, its designated representatives and employees the right to enter any premises where the Novartis Material is stored in order to
inspect or repossess it as NOVARTIS shall in its sole discretion deem fit. 


  

	2.7	 Authorizations and Permits. SUPPLIER represents and warrants that on the Effective Date and
throughout the Term, SUPPLER holds, or will cause its Approved Subcontractors to hold, all Manufacturing Licenses and any other approvals, permits, or exemptions from any Regulatory Authority which are required to perform its obligations under this
Agreement, and has paid all fees due in relation to them and is not in material breach of any conditions under them. Upon request, SUPPLIER shall provide, or shall cause its Approved Subcontractors to provide to NOVARTIS copies of any Manufacturing
Licenses or any other approvals, permits, or exemptions. Without prejudice to any of NOVARTIS’ other rights hereunder, SUPPLIER shall inform NOVARTIS promptly in writing if any such Manufacturing Licenses or other approvals or permits are not
obtained in a timely manner or are withdrawn or otherwise under investigation. 


  

	2.8	 Registration and Regulatory Requirements. NOVARTIS and its Affiliates shall be responsible for
the Registration of the Product with all relevant Regulatory Authorities of all countries of the Territory where they market the Products. SUPPLIER shall provide such assistance as NOVARTIS or its Affiliates may reasonably request in connection
therewith, [***]. In addition, SUPPLIER shall provide (and shall cause its Approved Subcontractors and suppliers to provide) NOVARTIS with any information or documentation in its possession, control or ownership and to render any other assistance
reasonably necessary to enable NOVARTIS to make an application to any Regulatory Authority, at NOVARTIS’ expense. 


  

	2.9	 Termination of Original Agreements. Effective as of the Effective Date, SUPPLIER, NOVARTIS and
Novartis Pharmaceuticals Corporation hereby agree that the Development, License and Supply Agreement and the License and Supply Agreement are terminated in all respects as of the Effective Date and that: 



 

	 	(a)	 [***] 



  

			
	EXECUTION VERSION	  	Page 11 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	 	(b)	 [***]; 


  

	 	(c)	 this Agreement shall apply to and govern the supply of, and associated payments for, those products as listed
in ANNEX 11 which were ordered prior to the termination of the Original Agreements but were not delivered to NOVARTIS or Novartis Pharmaceuticals Corporation, as applicable, in calendar year 2018; and 



 

	 	(d)	 notwithstanding the amendment and restatement of the Original Agreements as set forth in this Agreement, the
rights of inspection and audit and the confidentiality obligations, and any other provisions that by their nature were intended to survive the termination thereof, set forth in such Original Agreements shall continue in force for the period referred
to in the relevant provisions of such Original Agreements. 


 For the avoidance of doubt, subject to this Clause
2.9, the termination of the Original Agreements shall not affect the rights of either party against the other accrued or accruing under such Original Agreements before termination. 

 

	3.	 CAPACITY 


  

	3.1	 Minimum Capacity. During the Term, SUPPLIER shall maintain a monthly minimum capacity for the
Manufacturing of [***] percent 
([***]%) of the applicable Forecast (“Minimum Capacity”). SUPPLIER shall use commercially reasonable efforts to increase its capacity up to the required units of Product within a
reasonable time if NOVARTIS requires a higher minimum capacity at any time during the Term, provided Supplier’s failure to achieve an increased level of capacity that is in excess of [***] percent ([***])% of the then-applicable Forecast shall
not constitute a material breach of this Agreement under Clause 20.1. 


  

	4.	 COMPONENTS AND TOLL MATERIALS 



 

	4.1	 Procurement of Components. Where SUPPLIER procures Components, SUPPLIER shall ensure that such
Components are manufactured as required under this Agreement (including the Quality Agreement and the HSE Requirements). SUPPLIER shall and shall cause its Approved Subcontractors, at its cost, to purchase, qualify, test, inspect and approve all
such Components required in the Manufacturing, storage, shipping or receiving of the Product. In relation to its Approved Subcontractors and/or suppliers of such Components, SUPPLIER shall: 



 

	 	(a)	 [***] and keep NOVARTIS informed of the material terms and status of such supply, subject to any and all
confidentiality agreements as may be in place with any and all such Approved Subcontractors and/or suppliers; 


  

	 	(b)	 proactively manage its Approved Subcontractors and/or suppliers of Components, including by regularly auditing
and evaluating such Approved Subcontractors and/or suppliers and by having effective performance management and supplier relationship management regimes; 



  

			
	EXECUTION VERSION	  	Page 12 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	 	(c)	 ensure that Critical Components are only supplied from suppliers approved in writing by NOVARTIS, as may be
further detailed in the Quality Agreement; and 


  

	 	(d)	 keep NOVARTIS informed without undue delay of any possible interruptions with respect to the Components supply
as soon as SUPPLIER becomes aware of such interruption possibility. 


  

	4.2	 Stock of Components. During the Term, SUPPLIER will apply first-expiry, first out methods of usage to
any stock of Components. SUPPLIER shall ensure that its stock of Components is always sufficient to permit the uninterrupted Manufacturing of the Product in full compliance with Confirmed Orders, Confirmed Delivery Dates and Order Lead Time. For
those Products listed in ANNEX 2, SUPPLIER shall additionally maintain a rolling safety stock of Components as set forth in ANNEX 2. Further, SUPPLIER shall ensure that the quantities of Components ordered and stored by it relate
appropriately to Confirmed Orders and shall wind down its safety stock inventory prior to the expiration or termination of this Agreement so that the items in stock do not become obsolete or unsaleable. Subject to the foregoing, [***].



  

	4.3	 Alternative Sources. NOVARTIS may at any time identify to SUPPLIER suppliers from which SUPPLIER may
obtain any of the Components at a lower cost and/or higher quality, in accordance with this Agreement. In such event, SUPPLIER and NOVARTIS shall collaborate in order to obtain the necessary regulatory approvals and SUPPLIER shall utilize the
suppliers identified by NOVARTIS following receipt of such approvals [***]. Once such suppliers are fully qualified and/or Validated, SUPPLIER shall be solely and fully liable for the performance of such alternative suppliers, including for the
quality of the Components delivered by any of such suppliers and compliance with this Agreement, the Quality Agreement and the HSE Requirements. 


  

	4.4	 Supply of Toll Materials. Solely for purposes of SUPPLIER’s Manufacturing of the Products
hereunder, NOVARTIS undertakes from time to time to supply (or have supplied by a designated third party) to SUPPLIER, [***], the Toll Materials required in the Manufacture of the Product, in such quantities as may be ordered by SUPPLIER in
accordance with Clause 4.6. [***]. 


  

	4.5	 Toll Materials Forecast. SUPPLIER shall provide NOVARTIS with a written non-binding rolling [***] forecast of the volume of the Toll Materials, in accordance with NOVARTIS’ Forecast. SUPPLIER shall submit written orders for the Toll Materials with a lead time of at least [***].
NOVARTIS shall notify SUPPLIER on or before [***] after receipt of an order if it is unable to meet all or a portion of an order by the requested delivery date. 



  

			
	EXECUTION VERSION	  	Page 13 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	4.6	 Ownership of Toll Materials. Toll Materials delivered to SUPPLIER shall be held by SUPPLIER or the
Approved Subcontractors on behalf of NOVARTIS in accordance with the terms of this Agreement. The Toll Materials shall at all times remain the property of NOVARTIS. SUPPLIER must not use any such Toll Materials delivered for any purpose other than
to Manufacture, package and test the Products in accordance with this Agreement. SUPPLIER hereby irrevocably grants, and shall cause its Approved Subcontractors to grant, to NOVARTIS the right for NOVARTIS, its designated representatives and
employees to access any premises where the Toll Materials are stored in order to inspect or repossess the Toll Materials. 


  

	4.7	 Handling of Toll Materials. As from its delivery, SUPPLIER shall: (i) store and handle, at its own
cost, the Toll Materials in accordance with applicable cGxP, the Quality Agreement, NOVARTIS’ handling and storage instructions and, more generally, in a safe and orderly manner and take all necessary care to prevent its damage, loss or theft;
(ii) clearly identify all such Toll Materials in storage and in its books as goods belonging to NOVARTIS; (iii) never mix, alter or analyze the Toll Materials except for the purpose of any testing; and (iv) always use FEFO methods of
usage. 


  

	4.8	 Target Yield Loss Rate. SUPPLIER will use its best efforts to obtain maximum yield of the Product
from the Toll Materials in connection with its Manufacturing services provided under this Agreement. [***] 


  

	4.9	 Loss of Toll Materials. Except where due to the supply by NOVARTIS of Defective Toll Materials,
SUPPLIER shall reimburse NOVARTIS the Toll Materials Reimbursement Value together with any additional direct fees, including but not limited to, transportation fees and insurance fees for Toll Materials which as a result of the gross negligence,
omission of or breach of contract by SUPPLIER (i) cannot be used in the Manufacturing of the Product; or (ii) have been used in the Manufacturing without resulting in Product or in Product that is free of Defects (including without
limitation any Toll Materials used in failed or rejected Batches or in Defective Product). SUPPLIER shall immediately inform NOVARTIS of any loss or damage to Toll Materials and promptly provide in writing all explanations and evidence.



  

	4.10	 Monthly Toll Materials Inventory. SUPPLIER shall maintain up-to-date records of all Toll Materials and, within the first week of each month or at such other frequency as the parties may agree, shall provide to NOVARTIS a complete and accurate list of all such items
held by it on the last day of the immediately preceding calendar month. Such inventory list shall in particular specify the inventory balance of each such item at the relevant date and shall contain a detailed explanation for any inventory
discrepancy exceeding [***] percent ([***]%). SUPPLIER shall also provide NOVARTIS with written reports on a quarterly basis reconciling the quantities of Toll Materials provided to and held by SUPPLIER, the consumption of Toll Materials and the
estimated yield losses in the Manufacturing. 


  

	4.11	 Annual Toll Materials Inventory. In addition to the monthly inventory report, and at no
additional cost to NOVARTIS, SUPPLIER shall provide to NOVARTIS an annual report setting forth the result of an annual inventory count of all Toll Materials held by 



  

			
	EXECUTION VERSION	  	Page 14 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

	 	SUPPLIER as at October 31 of each Contract Year (or such other date as agreed in writing between the parties), such inventory count to be carried out under the joint supervision of the respective auditors for
SUPPLIER and NOVARTIS in accordance with the stock count procedure set forth in ANNEX 8. SUPPLIER shall deliver such annual report on or before one (1) month after completion of this annual inventory count (or within such other time as
the parties may agree in writing). SUPPLIER shall be responsible for any discrepancies (such as, for example, missing quantities) not accounted for during such annual inventory count or in connection with the monthly inventory report pursuant to
Clause 4.10, without regard to the reason for such discrepancy. Each party shall pay for its own auditor’s fees under this Clause 4.11. 


 

	4.12	 Defective Toll Materials. The following shall apply if NOVARTIS supplies any Toll Materials to
SUPPLIER and it is established that such Toll Materials are not in conformity with the Specifications: 


  

	 	(a)	 SUPPLIER shall inform NOVARTIS in case it discovers any non-conformity
of any of the Toll Materials with applicable Specifications, such notification to be made promptly upon discovery of such non-conformity. 



 

	 	(b)	 SUPPLIER shall return the non-conforming Toll Materials to NOVARTIS or
destroy them, as per NOVARTIS’ written request and instructions and at NOVARTIS’ sole cost and expense. In no event shall SUPPLIER destroy said Toll Materials without NOVARTIS’ prior written consent. 



 

	 	(c)	 Subject to Clause 4.12(d), NOVARTIS shall as soon as reasonably possible replace such defective Toll
Materials with Toll Materials meeting the Specifications in accordance with the provisions of this Agreement at NOVARTIS’ cost, including all reasonable, documented costs associated with any testing, return or destruction of the non-conforming Toll Materials. 


  

	 	(d)	 Such Toll Materials shall be replaced at SUPPLIER’s cost (at the Toll Materials Reimbursement Value
together with any additional direct fees, including, but not limited to, transportation fees, insurance fees, duty) if it is established that the non-conformity with the Specifications occurred after delivery
of the defective Toll Materials to SUPPLIER and is due to any actions, omissions, breach of this Agreement (including the Quality Agreement) or gross negligence of SUPPLIER. In addition, in such case, SUPPLIER shall bear sole responsibility for all
reasonable costs associated with any testing, return or destruction of the non-conforming Toll Materials. 


  

	4.13	 Dispute Resolution. Clause 23.3 shall apply if an unresolved dispute exists as to the
determination of a non-conformity with the Specifications of Toll Materials and/or the root cause of such non-conformity. 



 

	5.	 FORECASTING, ORDERS AND DELIVERY 



 

	5.1	 Product Forecast. Once per month, NOVARTIS shall provide SUPPLIER with a written monthly non-binding rolling [***] forecast (“Forecast”) of the required Product quantities. 


  

	5.2	 Orders. 


  

	 	(a)	 Order Placement and Order Lead Time. NOVARTIS may from time to time place written purchase orders for
the Product (“Order(s)”). Any Orders must be submitted with a lead time of at least [***] (“Order Lead Time”) and shall set forth the requested quantities of Product (“Requested




  

			
	EXECUTION VERSION	  	Page 15 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

	 	Order Quantities”) and the requested delivery date(s) in accordance with such Order Lead Time (“Requested Delivery Date(s)”). SUPPLIER shall use commercially reasonable efforts to
accommodate any request by NOVARTIS to submit an Order with an order lead time shorter than the Lead Time, but in no event shall such request by NOVARTIS be for less than [***] lead time. 


 

	 	(b)	 Order Confirmation Process. Within [***] business days of receipt of any Order, SUPPLIER shall
acknowledge receipt of such Order. Within twenty (20) business days of receipt of any Order, SUPPLIER shall then confirm to NOVARTIS in writing whether SUPPLIER is able to Deliver the Requested Order Quantities by the Requested Delivery Date or
agree with NOVARTIS on alternative quantities and/or an alternative delivery date. Notwithstanding anything to the contrary, SUPPLIER shall be obligated to confirm and Deliver any Order which complies with the Order Lead Time and for which the
Requested Order Quantities do not exceed [***]. Once SUPPLIER has confirmed the Product quantities and the delivery date in accordance with this Clause 5.2, the relevant Order shall be considered binding on the parties (“Confirmed
Order”), as will the confirmed Product quantities (“Confirmed Order Quantities”) and the confirmed delivery date(s) (“Confirmed Delivery Date(s)”), provided, for clarity, that if SUPPLIER fails to confirm
the Product quantities and the delivery date(s) within the [***] business day period set forth above, then the Requested Order Quantities and/or the Requested Delivery Date(s) shall be automatically deemed to be Confirmed Order Quantities and/or
Confirmed Delivery Date(s) respectively and shall be binding on both parties. 


  

	 	(c)	 Excess Order Quantities. Subject to and within the Minimum Capacity, SUPPLIER shall (and shall cause its
Approved Subcontractors to) use commercially reasonable efforts to satisfy NOVARTIS’ requirements of Products in excess of the Forecast, at no additional cost to NOVARTIS. If an Order exceeds the Minimum Capacity, SUPPLIER shall use
commercially reasonable efforts to increase Manufacturing capacity at the Facility up to the required capacity [***]. Notwithstanding the foregoing, (i) if SUPPLIER incurs actual, reasonable costs and expenses related to its having to increase
Manufacturing capacity (e.g., overtime or need for second shift) in order to accommodate NOVARTIS’ requirements for Products in excess of the Forecast in accordance with this sub-clause (c), such costs
and expenses shall be passed on to, and shall be payable by, NOVARTIS subject to SUPPLIER seeking advance written approval of NOVARTIS and providing documented evidence of such costs and expenses; and (ii) nothing in this sub-clause (c) shall require SUPPLIER to make any capital expenditures or additional investments outside of SUPPLIER’s normal shift pattern (as it relates to the manufacture and supply of products
generally at its Facility). If and to the extent SUPPLIER agrees to make any capital expenditures or additional investments that are required in order to accommodate NOVARTIS’ requirements for Products in excess of the Forecast in accordance
with this sub-clause (c), the cost of such capital expenditures or additional investments shall be passed on to, and shall be payable by, NOVARTIS subject to the terms of a separate written agreement between
the parties. 


  

	 	(d)	 Changes to Confirmed Orders Requested by SUPPLIER. In the event that SUPPLIER anticipates that it will
be unable to meet the Confirmed Delivery Dates and/or Confirmed Order Quantities, SUPPLIER shall promptly notify NOVARTIS (and in any event no later than [***] business days before the




  

			
	EXECUTION VERSION	  	Page 16 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

	 	Confirmed Delivery Date). In such case, any such change to the Confirmed Delivery Dates and/or Confirmed Order Quantities, whether or not accepted by NOVARTIS, are without prejudice to NOVARTIS’ rights and remedies
under this Agreement and/or governing law, including Clause 5.7 (Late Delivery); Clause 5.8 (Supply Failure), and Clause 11.2 (KPIs). 

  

	 	(e)	 Changes to Confirmed Orders Requested by NOVARTIS. SUPPLIER shall use commercially reasonable efforts to
comply with any unplanned changes to Confirmed Orders requested by NOVARTIS and shall confirm (or reasonably reject) any such changes within the timelines set forth in Clause 5.2(a), and where SUPPLIER accepts such changes, SUPPLIER’s
supply related KPIs shall be deemed adjusted accordingly. SUPPLIER shall not implement such unplanned changes without the prior written consent of NOVARTIS if such changes result in supplementary costs for NOVARTIS. Notwithstanding the foregoing,
(i) if SUPPLIER incurs actual costs and expenses related to its compliance with such unplanned changes to Confirmed Orders (e.g., overtime or need for a second shift) in order to accommodate NOVARTIS’ requested changes to Confirmed Orders
in accordance with this sub-clause (e), such costs and expenses shall be passed on to, and shall be payable by, NOVARTIS subject to SUPPLIER seeking advance written approval of NOVARTIS and providing
documented evidence of such costs and expenses; and (ii) nothing in this sub-clause (e) shall require SUPPLIER to make any capital expenditures or additional investments outside of SUPPLIER’s
normal shift pattern (as it relates to the manufacture and supply of products generally at its Facility). If and to the extent SUPPLIER agrees to make any capital expenditures or additional investments in order to accommodate NOVARTIS’
requested changes to Confirmed Orders in accordance with this sub-clause (e), the cost of such capital expenditures or additional investments shall be passed on to, and shall be payable by, NOVARTIS subject to
the terms of a separate written agreement between the parties. 


  

	5.3	 Terms of Delivery. SUPPLIER shall Deliver the Products FCA, 1300 Gould Drive, Gainesville, GA
(“Free Carrier”, INCOTERMS® 2010). SUPPLIER shall ensure that Delivery of the Product fully complies with the TSP. SUPPLIER shall not be entitled to Deliver
partial shipments of the Products unless expressly authorized by NOVARTIS in writing to do so. SUPPLIER shall provide the origin, either preferential or non-preferential, of the Product on the shipping
documentation or a certificate of origin. If the Product qualifies for preferential origin under a Free Trade Agreement, SUPPLIER shall maintain all necessary documentation to prove qualification under the Free Trade Agreement. SUPPLIER shall also
provide documents and assistance as requested by NOVARTIS to address customs or special shipping requirements relating to the Products, including to obtain any licenses, official authorizations, clearances, customs, or any other documents or
information that NOVARTIS may require for export, import or transport of the Product to the final destination. 


  

	5.4	 Packaging. SUPPLIER shall ensure that any packaging for transportation (if applicable), fully complies
with the requirements set forth in this Agreement, the Quality Agreement and (as applicable) the TSP. SUPPLIER shall facilitate the orderly Delivery and the taking over by the selected carrier of any Product Delivered to NOVARTIS pursuant to
Clause 5.3 above. 


  

	5.5	 Residual Shelf Life. Upon Delivery, the Products’ residual shelf life must be at least [***]
percent ([***]%) of the applicable Product’s total shelf life (such residual shelf life (or any change thereto agreed in writing between the parties) to be referred to as “Residual Shelf Life”). The shipment of Product
with less than the Residual Shelf Life requires the prior written approval of NOVARTIS. 



  

			
	EXECUTION VERSION	  	Page 17 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	5.6	 TSP. SUPPLIER shall comply with the TSP, a copy of which is attached hereto as ANNEX 5.



  

	5.7	 [***]. 


  

	5.8	 Supply Failure. Without prejudice to any other rights or remedies available to NOVARTIS under
this Agreement and/or governing law, in the event of a Supply Failure, SUPPLIER shall promptly notify NOVARTIS and NOVARTIS may, in its sole discretion:  



 

	 	(a)	 request SUPPLIER to use best efforts to supply to NOVARTIS at least the same quantity of a Product as the
quantity of such Product purchased by NOVARTIS from SUPPLIER in the previous [***] months during the duration of such Supply Failure; 


  

	 	(b)	 for any Confirmed Order (or portion thereof) which cannot be satisfied or be reasonably expected to be
satisfied within timelines acceptable to NOVARTIS, cancel such Confirmed Orders (or the relevant portions thereof) without any penalty to NOVARTIS; and/or 


  

	 	(c)	 terminate this Agreement in accordance with Clause 20.1. 



The term “Supply Failure” shall mean [***]. 
  

	6.	 PRICE AND PAYMENT TERMS 



 

	6.1	 Price. The Price for the Product(s) is set forth in [***]. The Price shall be exclusive of any
VAT. For purposes of this Agreement, “VAT” means within the European Union such taxation as may be levied in accordance with (but subject to derogation from) Council Directive 2006/112/EC and outside the European Union any taxation
levied by reference to added value or sales. 


  

	6.2	 Price Changes. [***] 



  

			
	EXECUTION VERSION	  	Page 18 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	6.3	 Payment Terms. SUPPLIER shall provide NOVARTIS with an invoice setting forth the Price due and payable
for each Delivery of Products made under this Agreement. Each such invoice shall, to the extent applicable, identify the Order number, Product numbers, Batch numbers, quantities of Products, shipping address, Price and the total amount to be
remitted by NOVARTIS and the applicable VAT or other sales tax (if any) or such other information as may be required by the applicable tax laws. NOVARTIS shall pay all such invoices on or before [***] after the receipt of such invoice, unless
otherwise agreed upon in writing by the parties. 


  

	6.4	 Disputed Invoices. If NOVARTIS disputes in good faith its obligation to pay all or part of any
invoice submitted by SUPPLIER under this Agreement, then non-payment of such invoice or part of such invoice pending resolution of such dispute shall not constitute a material breach of this Agreement by
NOVARTIS, provided, that if any such dispute is resolved in SUPPLIER’s favor, NOVARTIS shall be responsible for the payment of interest on the amount(s) that were in dispute. 



 

	7.	 QUALITY ASSURANCE 



 

	7.1	 Quality Agreement. The mutual tasks and responsibilities of the parties (or their Affiliates who
are a party to the Quality Agreement) with regard to Quality Assurance are in particular determined in the Quality Agreement entered into by the parties (including though an affiliate addendum to a frame Quality Agreement). SUPPLIER shall at all
times during the Term fully comply (and shall cause its Affiliates and Approved Subcontractors to fully comply) with its obligations under the Quality Agreement. A breach of the Quality Agreement shall be considered a breach of this Agreement.



  

	7.2	 Quality Control. SUPPLIER shall maintain a quality assurance and quality control program in
accordance with cGxP, Applicable Standards and the Quality Agreement. 


  

	7.3	 Quality Audits and Regulatory Inspections. In accordance with the terms of the Quality Agreement and at
no additional cost to NOVARTIS, SUPPLIER shall (and shall cause its Affiliates and Approved Subcontractors and suppliers to) permit (i) NOVARTIS, its Affiliates or its designated representatives to audit any facilities (including the Facility)
used by SUPPLIER, its Affiliates, its Approved Subcontractors or its suppliers in relation to the performance of its obligations under this Agreement (including the Quality Agreement); and (ii) Regulatory Authorities to inspect any such
facilities. 



  

			
	EXECUTION VERSION	  	Page 19 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	8.	 CHANGES TO PRODUCTS 



 

	8.1	 Changes to the Products (including the API and Components), the Manufacturing or the Facility may only
be made in accordance with the Quality Agreement. 


  

	8.2	 SUPPLIER shall solely bear all actual and related costs resulting from: 



 

	 	(a)	 [***] 


  

	 	(b)	 [***] 


  

	 	(c)	 [***]. 


  

	8.3	 NOVARTIS shall solely bear all actual and related costs resulting from: 



 

	 	(a)	 [***] 


  

	 	(b)	 [***] 


  

	 	(c)	 [***]. 


  

	9.	 EXCHANGE OF INFORMATION 



Without prejudice to NOVARTIS’ rights to information set forth in the Quality Agreement, the parties shall continually exchange
information and experiences in all matters pertaining to the Manufacturing of the Product and Quality Assurance and shall inform each other promptly in writing regarding all matters which could jeopardize the Manufacturing of the Product, whether
for scientific, legal, regulatory or other reasons. 
  

	10.	 DEFECTIVE PRODUCT 



 

	10.1	 Right of Rejection. Within the timeframes mentioned in this Clause 10, NOVARTIS shall have, at
its sole discretion, the right to reject any Defective Product or any Batch (or related Batch) which can reasonably be expected to contain any Defective Product (except to the extent due to a Defect in the API attributable to NOVARTIS). For the
avoidance of doubt, it is expressly agreed that any acknowledgement of receipt of Product by NOVARTIS shall not constitute any acceptance of Product as free of Defects or any waiver of any rights by NOVARTIS. 



  

			
	EXECUTION VERSION	  	Page 20 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	10.2	 Notification. NOVARTIS shall notify SUPPLIER of any claims of Defective Product within the
following timelines: 


  

	 	(a)	 For Apparent Defects, NOVARTIS shall have the right to make a Defective Product claim under this Clause
10, provided that such claim is made in writing to SUPPLIER within [***] following receipt of the Defective Product by NOVARTIS at the NOVARTIS warehouse; and 



 

	 	(b)	 For Latent Defects of which it becomes aware during the Residual Shelf Life of a Product, NOVARTIS shall have
the right to make a Defective Product claim under this Clause 10, provided that such claim is made in writing to SUPPLIER within [***] following discovery of the Defect. 



Any Defect which has been notified within the above time periods shall be presumed to have been in existence at the time of Delivery, unless
SUPPLIER can demonstrate that such presumption is incompatible with the nature of the Defect. 
  

	10.3	 Handling of Defective Products. Without any prejudice to any other rights or remedies available
to NOVARTIS under this Agreement and/or governing law, and except to the extent that the Defect in the Product is due to a Defect in the API attributable to NOVARTIS, in the event that NOVARTIS notifies SUPPLIER of any Defect in
accordance with this Clause 10, SUPPLIER shall 


  

	 	(a)	 at NOVARTIS’ sole discretion and direction either: [***] 



 

	 	(b)	 [***]. 



Further, and without prejudice to NOVARTIS’ other rights hereunder and/or governing law, SUPPLIER shall promptly instruct NOVARTIS to
either send back to SUPPLIER or dispose of any Defective Products (and, if applicable, Products from the same or related Batch(es)), at SUPPLIER’s discretion. Any remedial action taken by SUPPLIER shall comply with the Quality Agreement and
SUPPLIER shall not rework or reprocess any rejected Defective Products, unless expressly authorized in writing to do so by NOVARTIS. 
  

	11.	 CONTINUOUS IMPROVEMENT, KPI, RELATIONSHIP MANAGEMENT 



 

	11.1	 Continuous Improvement. The parties agree to pursue a mutual continuous improvement strategy and
shall confer on a regular basis (at least annually) to consider whether new technologies or manufacturing processes may exist which would likely improve the Manufacturing performance and Product cost. [***]




  

			
	EXECUTION VERSION	  	Page 21 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	11.2	 KPIs Scoring and Reporting. NOVARTIS wishes to create additional transparency regarding supplier
performance by providing feedback on supplier performance [***]. 


  

	11.3	 Relationship Management. The parties shall establish a relationship management team and procedure
as set forth in ANNEX 4. 


  

	12.	 RESPONSIBLE PROCUREMENT 



NOVARTIS promotes the societal and environmental values of the United Nations Global Compact to its external suppliers and uses its influence
where possible to encourage their adoption. SUPPLIER shall: 
  

	 	(a)	 comply with the Novartis Supplier Code (and any published updates) which can be viewed and downloaded from
[***] (SUPPLIER may request a copy free of charge from NOVARTIS); 


  

	 	(b)	 having regard to Section 9.6 of the Novartis Supplier Code, provide information and documentation on
reasonable request to NOVARTIS and its Affiliates to allow NOVARTIS and its Affiliates to verify compliance with the Novartis Supplier Code in the form requested; 



 

	 	(c)	 to rectify identified non-compliances with the Novartis Supplier Code
(where capable of remedy) and report remediation progress to NOVARTIS on request; and 


  

	 	(d)	 ensure that where SUPPLIER, its Affiliates and/or Approved Subcontractors of SUPPLIER and its Affiliates have
been pre-approved by NOVARTIS (in accordance with this Agreement) to provide services that such third parties also comply with the above requirements relating to the Novartis Supplier Code.



 [***] 

  

			
	EXECUTION VERSION	  	Page 22 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	13.	 HSE, RISK MANAGEMENT AND BUSINESS CONTINUITY 



 

	13.1	 HSE Requirements. SUPPLIER shall fully comply (and shall cause its Approved Subcontractors
and suppliers to fully comply) with the HSE Requirements set forth in this Agreement, including without limitation (i) any Applicable Standards relating to HSE protection (including REACH (Regulation (EC) No. 1907/2006)); (ii) any terms of
the Quality Agreement relating to HSE; and (iii) ANNEX 8 (collectively, the “HSE Requirements”). 


  

	13.2	 HSE Audits. As further set out in ANNEX 8 and at no additional cost to NOVARTIS, SUPPLIER
shall (and shall cause its Affiliates, Approved Subcontractors and suppliers to) permit NOVARTIS, its Affiliates and/or its designated representatives no more frequently than once every [***] months (or more frequently solely “for cause”)
to audit any facilities (including the Facility) used by SUPPLIER, its Affiliates, its Approved Subcontractors and/or its suppliers in order to verify compliance with the HSE Requirements under this Agreement. 



 

	13.3	 Risk Management. In order to ensure continuity of supply and in connection with diligent Risk
Management (as defined below) practices, SUPPLIER will develop, implement and keep current a Risk Management program, including a Business Continuity Management (as defined below), of which a Business Continuity Plan (as defined below) is a key
element and output. The Business Continuity Plan shall detail strategies for responses to and recovery from a range of potential disruptive incidents. Upon NOVARTIS’ written request, SUPPLIER will promptly make a summary or abridged version of
such Business Continuity Plan available to NOVARTIS, its Affiliates or their designated representatives for review. The Business Continuity Plan does not relieve SUPPLIER from any liability under this Agreement. Once per calendar year (or at any
other frequency as NOVARTIS reasonably deems to be appropriate), SUPPLIER will conduct a test and evaluation of the Business Continuity Plan. The parties agree that any issues arising from the Risk Management and Business Continuity Management will
be promptly communicated to the other party. In no event shall SUPPLIER increase the Price as a result of the development, existence or implementation of the Business Continuity Plan. 



For purposes of this Clause 13.3:  
  

	 	(a)	 “Risk Management” means the identification, assessment, and prioritization of risks followed
by coordinated application of resources to minimize, monitor, and control the probability and/or impact of undesired incidents or to maximize the realization of opportunities; 



 

	 	(b)	 “Business Continuity Management” means the holistic management process which identifies
potential threats to an organization and the impacts to business operations those threats, if realized, might cause and which provides a framework for building organizational resilience with the capability of an effective response that safeguards
the interests of its key stakeholders, reputation, brand and value-creating activities. 


  

	 	(c)	 “Business Continuity Plan” means a plan clearly defining and documenting a set of measures
designed to (i) allow a quick response to a disruptive incident so that the key business processes are restored to a minimum required operational level, and (ii) recover the key business processes in a defined time frame; such plan shall
cover all key personnel, resources, services and actions which are required to manage the Business Continuity Management process. 



  

			
	EXECUTION VERSION	  	Page 23 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	14.	 PRODUCT RECALLS AND RETURNS 



 

	14.1	 Recalls. Upon discovery that a Product should be recalled or corrected, or may be required to be
recalled or corrected, the discovering party shall give prompt written notice to the QA contact of the other party, all subject to the terms of the Quality Agreement. The decision to initiate a recall or to take some other corrective action, if any,
shall be made and implemented by NOVARTIS. The recall procedure is set forth in the Quality Agreement. If a recall occurs, at NOVARTIS’ request, SUPPLIER shall replace the recalled Products (regardless of whether or not such Products are
Defective) with new Products in the same manner as set forth in Clause 10. 


  

	14.2	 Customer Complaints and Returns. SUPPLIER shall fully comply with the provisions of the Quality
Agreement relating to customer complaints and customer returns. NOVARTIS or its Affiliates shall have full responsibility for handling such customer complaints and returns. SUPPLIER shall provide NOVARTIS with such assistance as required under the
terms of the Quality Agreement. If a return occurs, at NOVARTIS’ request, SUPPLIER shall replace the returned Products (regardless of whether or not such Products are Defective) with new Products in the same manner as set forth in Clause
10. 


  

	15.	 INTELLECTUAL PROPERTY 



 

	15.1	 License Grant. Subject to the terms and conditions of this Agreement, SUPPLIER hereby grants to NOVARTIS
and its Affiliates a worldwide, exclusive, fully paid up and royalty free sub-licensable license to the Recro Patent Rights, including to make, have made, dispose of, have disposed of, offer to dispose of,
sell, offer to sell, commercialize, use, import, or keep the Products. 


  

	15.2	 Sub-license Grant. Subject to the terms and conditions of this
Agreement, SUPPLIER hereby grants to NOVARTIS and its Affiliates a worldwide, exclusive, fully paid up and royalty free sub-licensable sub-license to the Alkermes Patent
Rights, including to make, have made, dispose of, have disposed of, offer to dispose of, use, import, or keep the Products. 


  

	15.3	 Background IP. Each party’s background Intellectual Property, which are owned by or licensed to
that party prior to the Effective Date, or which are not invented, discovered, generated or derived under or in connection with this Agreement are and shall remain owned by or licensed to that party. Except as expressly stated herein, nothing in
this Agreement shall constitute or grant any implied license or ownership in proprietary rights or permission to file any patent, copyright or any other Intellectual Property rights to either party under the other party’s background
Intellectual Property. 


  

	15.4	 IP Ownership. 



 

	 	(a)	 Novartis IP. All Intellectual Property solely invented, discovered, generated or derived by or on behalf
of NOVARTIS or its Affiliates under or in connection with this Agreement shall be the exclusive property of NOVARTIS or its Affiliates. All Intellectual Property invented, discovered, generated or derived by or on behalf of SUPPLIER, whether solely
or jointly with NOVARTIS or its Affiliates, under or in connection with this Agreement, shall be the exclusive property of NOVARTIS or its Affiliates if the Intellectual Property arises from or relates to Novartis Material or other Confidential
Information of or disclosed by NOVARTIS. [***] 



  

			
	EXECUTION VERSION	  	Page 24 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	 	(b)	 Supplier IP. All Intellectual Property invented, discovered, generated or derived by SUPPLIER in
connection with the Product which is not covered by Clause 15.4(a) and which is independently invented, discovered, generated or derived by or on behalf of SUPPLIER shall be the sole and exclusive property of SUPPLIER. NOVARTIS and its
Affiliates shall have a worldwide, perpetual, non-exclusive, royalty free, fully paid-up license under such Intellectual Property, with the right to grant sub-licenses. 


  

	 	(c)	 Notification by Supplier. SUPPLIER shall promptly disclose in writing and make available to NOVARTIS in
electronic form, and shall cause its Approved Subcontractors to disclose in writing and make available to NOVARTIS in electronic form, all results, inventions and improvements (whether patentable or not) which are invented, discovered, generated or
derived under or in connection with this Agreement. NOVARTIS and its Affiliates shall have the first right but not the obligation, at NOVARTIS’ costs, to prepare, file, prosecute, obtain and maintain patent applications and patents relating to
inventions and improvements which are invented, discovered, generated or derived under or in connection with this Agreement. 


  

	 	(d)	 Supplier Assistance. SUPPLIER shall execute all documents and take all such other actions as may be
reasonably requested by NOVARTIS or its Affiliates in order to permit NOVARTIS (or its Affiliates) to obtain the benefit of its rights (including Intellectual Property) under or in connection with this Agreement, and shall cause any employees,
Approved Subcontractors, suppliers of Components or any other subcontractor to take such action, all at NOVARTIS’ expense. SUPPLIER shall ensure that it has enforceable written agreements with its Approved Subcontractors granting to SUPPLIER
rights (with the right to sub-license) to all results and Intellectual Property created by such Approved Subcontractors during the course of their engagement hereunder. 



 

	 	(e)	 IP Infringement. Should SUPPLIER become aware of any infringement of NOVARTIS’ or its
Affiliates’ Intellectual Property relating to the Product or Manufacturing processes, SUPPLIER shall immediately notify NOVARTIS thereof. 


  

	15.5	 IP Enforcement and Defense. 



 

	 	(a)	 Each party will promptly notify the other of any infringement by a third party of any of the Alkermes Patent
Rights, Recro Patent Rights or Intellectual Property in connection with this Agreement of which it becomes aware, including any “patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2)
or similar provisions in other jurisdictions and of any request for declaratory judgment, opposition, nullity action, interference, inter-partes reexamination, inter-partes review, post-grant review, derivation proceeding, or similar action alleging
the invalidity, unenforceability or non-infringement of any of the Alkermes Patent Rights, Recro Patent Rights, Intellectual Property or Know-How in connection with this
Agreement (collectively “Third Party Infringement”). Each party will provide the other with any available evidence of such Third Party Infringement. 



  

			
	EXECUTION VERSION	  	Page 25 of 54















	 	(b)	 NOVARTIS will have the right to bring and control any legal action in connection with any Third Party
Infringement of Recro Patent Rights at its own expense as it reasonably determines appropriate, and the SUPPLIER shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If NOVARTIS fails to bring
or terminate any such action or proceeding with respect to such Third Party Infringement of Recro Patent Rights (i) within one hundred twenty (120) days following the notice of alleged infringement or (ii) prior to ten (10) days
before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, SUPPLIER shall have the right, upon written approval of NOVARTIS (such approval not to be unreasonably withheld
or delayed), to bring and control any such action at its own expense and by counsel of its own choice, and NOVARTIS shall have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, however, that
if NOVARTIS notifies SUPPLIER in writing prior to ten (10) days before such time limit for the filing of any such action that NOVARTIS intends to file such action before the time limit, then NOVARTIS shall be obligated to file such action
before the time limit, and SUPPLIER will not have the right to bring and control such action. 


  

	 	(c)	 At the request of NOVARTIS, SUPPLIER shall provide reasonable assistance in connection therewith, including by
executing reasonably appropriate documents, access to SUPPLIER’S premises and employees, cooperating reasonably in discovery and joining as a party to the action if required. 



 

	 	(d)	 In connection with any such proceeding, NOVARTIS shall not enter into any settlement admitting the invalidity
of, or otherwise impairing SUPPLIER’S rights in, the Recro Patent Rights and/or the Alkermes Patent Rights without the prior written consent of SUPPLIER, which will not be unreasonably withheld or delayed. 



 

	 	(e)	 Any recoveries resulting from such an action relating to a Claim of Third Party Infringement of Recro Patent
Rights shall be first applied against payment of each party’s costs and expenses in connection therewith. In the event that NOVARTIS brought such action, any remainder will be retained by (or if received by SUPPLIER, paid to) NOVARTIS. In the
event that SUPPLIER brought such action, any remainder shall be divided equally between SUPPLIER and NOVARTIS. 


  

	15.6	 Trademarks. NOVARTIS shall have the right to brand the Products using NOVARTIS related trademarks
and any other trademarks and trade names it determines appropriate for the Product, which may vary by country or within a country (“Product Marks”). NOVARTIS or its Affiliates shall own all rights in the Product Marks and register
and maintain the Product Marks in the countries and regions it determines reasonably necessary. 


  

	15.7	 Representations and Warranties of SUPPLIER. SUPPLIER represents and warrants to NOVARTIS as of the
Effective Date that: 


 (a)    ANNEX 10 sets forth a complete and accurate list of all Patent
Rights owned by SUPPLIER covering the Product in existence as of the Effective Date, indicating the owner, and/or co-owner(s) thereof if such Patent Rights are not solely owned by SUPPLIER; 

  

			
	EXECUTION VERSION	  	Page 26 of 54














 (b)    SUPPLIER is the sole and exclusive owner of all of the Recro
Patent Rights, free from encumbrances (except for security interests), and is listed in the records of the appropriate governmental agencies as the sole and exclusive owner of record for each registration, grant and application included in the Recro
Patent Rights; 
 (c)    ANNEX 9 sets forth a complete and accurate list of all Patent Rights owned by Alkermes
and its Affiliates covering the Product in existence as of the Effective Date, indicating the owner, and/or co-owner(s) thereof if such Patent Rights are not solely owned by Alkermes; 

(d)    SUPPLIER has the right to grant to Novartis and its Affiliates the licenses under the Recro Patent Rights and
Alkermes Patent Rights that it purports to grant hereunder; 
 (e)    to SUPPLIER’s knowledge, the issued patents in
the Recro Patent Rights and Alkermes Patent Rights are valid and enforceable without any Claims, challenges, oppositions, nullity actions, interferences, inter-partes reexaminations, inter-partes reviews, post-grant reviews, derivation proceedings,
or other proceedings pending or threatened; 
 (f)    to SUPPLIER’s knowledge, SUPPLIER has not committed any act,
or omitted to commit any act, that may cause the Recro Patent Rights or Alkermes Patent Rights to expire prematurely or be declared invalid or unenforceable; and 

(g)    all applications, registrations, maintenance and renewal fees for which there is a maximum payment deadline prior to
the Effective Date in respect of the Alkermes Patent Rights listed in ANNEX 9 and the Recro Patent Rights listed in ANNEX 10 have been paid. All applications, registrations, maintenance and renewal fees in respect of the Recro Patent
Rights and Alkermes Patent Rights will be maintained by SUPPLIER until the respective patent expiry dates. To SUPPLIER’s knowledge, all necessary documents and certificates have been filed with the relevant agencies for the purpose of
maintaining the Recro Patent Rights and Alkermes Patent Rights. 
  

	16.	 INDEMNIFICATION AND LIABILITIES 



 

	16.1	 Supplier Indemnification. SUPPLIER shall defend, indemnify and hold NOVARTIS and its Affiliates
harmless against any and all Claims to the extent arising out of: (i) any breach of this Agreement by SUPPLIER or its Affiliates; (ii) any Defect in the Products; (iii) any negligence or willful misconduct of SUPPLIER or its
Affiliates; or (iv) any patent infringement or infringement of any other Intellectual Property with respect to the Products and/or SUPPLIER’s manufacturing processes, except to the extent that such Claims arise out of: (A) any breach
of this Agreement by NOVARTIS or its Affiliates; (B) any negligence or willful misconduct of NOVARTIS or its Affiliates; or (C) any Claim otherwise covered by the indemnity in Clause 16.2. 



 

	16.2	 Novartis Indemnification. NOVARTIS shall defend, indemnify and hold SUPPLIER and its Affiliates
harmless against any and all Claims to the extent arising out of: (i) the use of the Products in a NOVARTIS pharmaceutical proprietary product by any person, (ii) any breach of this Agreement by NOVARTIS or its Affiliates; or
(iii) any negligence or willful misconduct of NOVARTIS or its Affiliates, except to the extent that such Claims arise out of: (A) any breach of this Agreement by SUPPLIER or its Affiliates; (B) any Defect in the Products; (C) any
negligence or willful misconduct of SUPPLIER or its Affiliates; or (D) any Claim otherwise covered by the indemnity in Clause 16.1. 



  

			
	EXECUTION VERSION	  	Page 27 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	16.3	 Indemnification Process. The indemnification obligations of NOVARTIS and SUPPLIER, as the case may be,
shall apply only if: 


  

	 	(a)	 the party asserting its rights (“Indemnitee”) promptly notifies the other party
(“Indemnitor”) in writing after Indemnitee receives notice of any Claims; 


  

	 	(b)	 Indemnitee has refrained and continues to refrain from making any admission of liability or any attempt to
settle any such Claims without Indemnitor’s written consent; 


  

	 	(c)	 Indemnitor is given the opportunity to manage and control the defense or settlement of such Claims;



  

	 	(d)	 Indemnitee reasonably co-operates with Indemnitor in the defense of any
such Claims; and 


  

	 	(e)	 Indemnitee takes all such reasonable steps and actions as are necessary or as the Indemnitor may reasonably
require or request in order to mitigate any Claims. 


  

	16.4	 Nothing in this Agreement shall exclude or limit any liability for (i) willful misconduct or
omission; (ii) fraud; (iii) intentional breach; (iv) gross negligence; (v) personal injury or death caused by the negligence of a party; or (vi) any other liability that cannot be limited or excluded by law.



  

	17.	 INSURANCE 


  

	17.1	 Each party (or its Affiliate on behalf of such party) shall maintain in full force and effect, at its
sole cost and expense, and at all times during the Term hereof, a policy of commercial general liability insurance, including contractual liability, with limits of not less than [***] in the aggregate. Notwithstanding the foregoing, SUPPLIER (or its
Affiliate on behalf of SUPPLIER) shall maintain throughout the term of this Agreement products/completed operations liability coverage in an amount not less than [***]. Both parties shall also maintain such other policies of insurance or programs of
self-insurance of the types and in the amounts customarily carried by their respective businesses to fulfill their respective obligations stated within this Agreement. 



 

	17.2	 Each party warrants that neither its program of self-insurance, if any, nor its (or its
Affiliate’s) insurance policy(ies) as described in the foregoing paragraph will affect or limit its liability or indemnity obligations stated elsewhere in this Agreement or as required by law. By requiring SUPPLIER to maintain
products/completed operations liability insurances, Novartis does not represent that SUPPLIER’s insurance program will be adequate to fund all losses for which SUPPLIER may be liable hereunder. Upon execution of this Agreement and annually
thereafter upon request, each party shall provide the other with evidence of its (or its Affiliate’s) liability insurance as described in the foregoing paragraphs. NOVARTIS shall evidence its general commercial and products/completed
operations liability insurance to SUPPLIER using a Memorandum of Insurance (MOI) website link. Each party shall be given thirty (30) days’ prior written notice of any cancellation, termination or
non-renewal of any of the insurance policies described herein by the other party. 



  

			
	EXECUTION VERSION	  	Page 28 of 54















	18.	 CONFIDENTIALITY 



 

	18.1	 Confidential Information. Neither party shall disclose to any third party nor use for any purpose
outside of the scope of this Agreement any information which is not in the public domain and which was disclosed in connection with this Agreement: (i) by a party or any of its Affiliates; or (ii) any unaffiliated third party at the
request of such disclosing party (“Confidential Information”). The receiving party may only provide the disclosing party’s Confidential Information to its and its Affiliates’ directors, officers, employees, advisors, and
consultants (“Representatives”) who are informed of the confidential nature of the Confidential Information and who are bound by obligations of confidentiality and non-use no less restrictive
than those contained herein and provided that the receiving party shall be responsible for any breach of this Agreement by its Representatives, which shall be considered a breach by the receiving party. The obligations of confidentiality and non-use shall expire for Confidential Information which: 


  

	 	(a)	 is or becomes part of the public domain without a violation of this Agreement; 



 

	 	(b)	 was already in its possession at the time of receipt from the disclosing party, as shown by documentary
evidence; or 


  

	 	(c)	 after the date of this Agreement is received from a third party whose direct or indirect source is not the
disclosing party. 


  

	18.2	 Disclosure of Confidential Information. The parties may disclose Confidential Information where
reasonably required under applicable law (including any securities law or regulation or the rules of a securities exchange): (i) to competent Regulatory Authorities for Registration or other regulatory purposes, including the U.S. Securities and
Exchange Commission (the “SEC”) or a securities exchange, and, when required by such applicable law, to the public; and (ii) to competent court or governmental agencies, in which case the disclosing party (to the extent
permissible under applicable law) shall inform the other party of such disclosure in writing and shall use commercially reasonable efforts to limit the scope of such disclosure to obtain confidential treatment by the court or governmental agency.
Except as expressly permitted herein, this Clause 18.2 shall not be interpreted as relieving the receiving party of its confidentiality obligations under this Clause 18. In addition, NOVARTIS and/or its Affiliates may disclose
Confidential Information to any purchaser interested in acquiring all or part of NOVARTIS’ business or assets relating to the Products (including without limitation by asset purchase, divestment,
out-licensing, merger, consolidation or reorganization), provided that such potential purchaser (x) has submitted an offer for such business or assets, and (y) has entered into a confidentiality
agreement with NOVARTIS and/or its Affiliates on terms and conditions not less stringent than those foreseen herein. The parties acknowledge that either or both parties may be obligated to make filings (including, but not limited to, filing a copy
of this Agreement) with the SEC or other governmental entity. Each party shall be entitled to make such required filings, provided that it requests confidential treatment of sensitive terms of this Agreement (including any Annex hereto) to the
extent such confidential treatment is reasonably available to such party. In the event of any such filing of this Agreement, the party making such filing shall provide notice to the other party with a copy of such disclosure and, if applicable, a
copy of this Agreement (including the Annexes hereto) marked to show provisions for which such party intends to seek confidential treatment not less than five (5) business days prior to such filing (and any revisions to such portions of the
proposed filing a reasonable time prior to the filing thereof), and shall give consideration to the other party’s comments thereon to the extent consistent with legal requirements. No such notice shall be required under this Clause 18.2
if the substance of the description of or reference to this Agreement contained 



  

			
	EXECUTION VERSION	  	Page 29 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

	 	in the proposed filing has been previously included in or is substantially similar to any filing previously made by a party pursuant to the terms of this Clause 18.2 or that has otherwise been previously approved
in writing by the other party. 

  

	18.3	 Survival. The obligations of confidentiality and non-use
contained in this Clause 18 shall survive the expiration or termination of this Agreement for a period of [***] years. 


  

	18.4	 Return of Confidential Information. Upon termination or expiration of this Agreement for any reason, the
receiving party will promptly return to the disclosing party all Confidential Information received from the disclosing party in connection with this Agreement. 



 

	19.	 TERM AND TERMINATION FOR CONVENIENCE 



 

	19.1	 Effective Date. This Agreement shall come into force on the Effective Date. 



 

	19.2	 Term. This Agreement shall have an initial fixed term of five (5) years from the Effective Date
(the “Initial Term”). Thereafter, unless terminated in accordance with Clause 19.3 or Clause 20, it shall renew automatically for successive periods of twelve (12) months (“Renewal Term”). The
Initial Term and any Renewal Term(s) are collectively referred to as the “Term”. 


  

	19.3	 Termination for Convenience. NOVARTIS may terminate this Agreement without cause upon written notice to
SUPPLIER at least twenty-four (24) months prior to the end of the Initial Term or any Renewal Term. SUPPLIER may terminate this Agreement without cause upon written notice to NOVARTIS at least twenty-four (24) months prior to the end of
the Initial Term or any Renewal Term. For clarity, the earliest termination effective date shall be 31 December 2023, and in the event either party wishes to terminate this Agreement at the end of the Initial Term, such party shall be required
to provide written notice to the other party no later than 31 December 2021. SUPPLIER acknowledges and agrees that this notice period is necessary in order to allow NOVARTIS sufficient time to identify, approve and transfer the Manufacturing of
the Product to a new supplier. 


  

	20.	 EXTRAORDINARY TERMINATION; DIVESTMENT 



Without prejudice to any grounds for extraordinary termination available to a party under applicable law, the parties agree that this Agreement
may be terminated in accordance with the terms set forth in this Clause 20.  
  

	20.1	 Termination due to Material Breach. Upon failure of any party to remedy its material breach of any of
its obligations under this Agreement (where remediable) on or before ninety (90) days after receipt of written notice of said breach from the other party, the party giving such notice shall have the right but not the obligation to terminate
this Agreement immediately (or such longer period of time as such party shall determine) by written notice. In respect of a material breach which is not capable of remedy, the non-defaulting party shall have
the right, but not the obligation, to terminate this Agreement immediately by written notice to the defaulting party. 


  

	20.2	 Termination due to Liquidation. SUPPLIER or NOVARTIS at its sole option may immediately terminate this
Agreement upon written notice, but without prior advance notice, to the other party upon the liquidation, dissolution, winding-up, insolvency, bankruptcy, assignment for the benefit of creditors, or filing of
any petition therefor, appointment of a receiver, custodian or trustee, or any other similar proceeding, by or of the other party where such petition, assignment or similar proceeding is not dismissed or vacated within ninety (90) days.




  

			
	EXECUTION VERSION	  	Page 30 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

	20.3	 Termination due to Regulatory Authority. NOVARTIS may terminate this Agreement immediately (in whole or
in part on either a country-by-country basis or a Product-by-Product basis) if any
Regulatory Authority takes any action, or raises any objection, that prevents NOVARTIS from supplying API (as applicable) and/or exporting, purchasing or selling a Product in its bulk or finished packaged form. Additionally, NOVARTIS shall have the
right to terminate this Agreement immediately (in whole or in part) if any Product (or, as applicable, the pharmaceutical product comprised of the Product) cannot be reasonably commercialized for medical, scientific or legal reasons.



  

	20.4	 Termination for Divestment. In the event of a sale, divestiture,
out-license or other disposition of all or part of the business or assets relating to the Product (or, as applicable, the pharmaceutical product comprised of the Product) supplied under this Agreement,
NOVARTIS shall have the right to unilaterally terminate this Agreement in whole or in part upon twelve (12) months prior written notice to SUPPLIER, provided, however, that neither NOVARTIS nor any assignee of NOVARTIS pursuant to Clause
24.9 may unilaterally terminate this Agreement pursuant to this Clause 20.4 during the Initial Term. 


  

	20.5	 Termination due to Non-Compliance with HSE Requirements.
NOVARTIS may terminate this Agreement upon sixty (60) days’ written notice to SUPPLIER if SUPPLIER fails to comply with Applicable Standards relating to HSE and does not cure such failure during such sixty (60) day period.



  

	20.6	 Compensation for Termination. [***] 



 

	21.	 EFFECTS OF TERMINATION OR EXPIRATION 



 

	21.1	 Return of Novartis Material. Upon expiration or termination of this Agreement for any reason, SUPPLIER
shall, and shall cause its Approved Subcontractors to, promptly Deliver to NOVARTIS or destroy at NOVARTIS’ direction, all Novartis Material. For Product, NOVARTIS shall pay the Price in effect at the time the relevant Order was placed;
for partially-Manufactured Product, the parties shall agree on a mutually agreed price, which shall consider whether the partially-Manufactured Product can be finished and, if so, NOVARTIS’ costs to complete such Manufacturing.



  

	21.2	 Survival. Except as otherwise expressly provided herein, the termination or expiration of this Agreement
will not affect any rights and obligations which, from the context thereof, are intended to survive termination or expiration of this Agreement, nor shall it prejudice any other remedies that the parties may have under this Agreement. Upon
expiration or termination of this Agreement, all outstanding unpaid invoices shall become payable immediately in place of the payment terms previously agreed by the parties. 



  

			
	EXECUTION VERSION	  	Page 31 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

	21.3	 Bridging Stock. Prior to expiration of this Agreement or upon notice of termination, NOVARTIS will have
the option (valid until the effective date of such expiration or termination) to place Orders for an additional quantity of the Products of up to [***] demand based on [***] percent ([***]%) of the quantity forecasted by NOVARTIS for the year in
which the contract expires or is terminated (“Bridging Stock”) at the price equal to the Price in force for the Product at the time of expiration or termination of this Agreement. NOVARTIS shall exercise its option for the Bridging
Stock by providing SUPPLIER with an Order for the desired quantities of the Bridging Stock, which shall be Manufactured or packaged pursuant to a Confirmed Order and shall meet the Specifications and be subject to the terms of this Agreement. The
parties shall agree in good faith on the Delivery dates of such Bridging Stock, provided, however, that SUPPLIER shall accept Requested Delivery Dates falling within the [***] period following the expiration or termination effective date, and the
parties hereby agree that terms of this Agreement shall apply to such Bridging Stock. 


  

	22.	 Technical Transfer. Upon the expiration or termination of this Agreement, at NOVARTIS’
written request, in NOVARTIS’ sole discretion, and provided the reason for such termination is not NOVARTIS’ material breach of this Agreement, SUPPLIER shall (and shall cause its Affiliates and Approved Subcontractors to) implement the
transfer of all know-how necessary for the Manufacture of the Products and related analytical testing methods from SUPPLIER, its Affiliates and/or Approved Subcontractors to NOVARTIS, its Affiliates and/or a
designated third party. SUPPLIER (or its Affiliates) shall cooperate with NOVARTIS (or its Affiliates or designated third party) with regard to such transfer and provide all reasonably required and customary assistance to NOVARTIS (or its Affiliates
or designated contract manufacturer) to enable NOVARTIS (or its Affiliates or designated contract manufacturer) to complete such transfer in a timely and effective manner. [***] 



 

	23.	 GOVERNING LAW AND JURISDICTION 



 

	23.1	 Governing Law. This Agreement and the legal relations between the parties in connection herewith shall
be governed by, and construed in accordance with, the laws of the State of New York, USA, without regard to its conflict of laws principles. 


  

	23.2	 Jurisdiction. For the purpose of any dispute arising out of or in connection with this Agreement which
cannot be resolved amicably, the parties hereby irrevocably submit to the exclusive jurisdiction of the Federal courts located in New York. 


  

	23.3	 Dispute Resolution through Independent Laboratory. The following shall apply in relation to any
unresolved dispute as to the existence and root cause of any non-conforming or Defective Product: 


  

	 	(a)	 either party may request in writing for such unresolved dispute to be determined by an independent first-class
laboratory (“Laboratory”); 


  

	 	(b)	 upon receipt of such request, the parties shall jointly appoint the Laboratory within twenty (20) days. If
the choice of the Laboratory cannot be agreed by the parties within the timeframe stated, each party shall be entitled to appoint one independent laboratory and the two independent laboratories so selected by the parties shall jointly select the
Laboratory. The Laboratory (and any laboratories appointed by the parties in order to jointly select the Laboratory) shall be bound to the parties by obligations of confidentiality no less exacting than those applying between the parties pursuant to
this Agreement; 



  

			
	EXECUTION VERSION	  	Page 32 of 54















	 	(c)	 the Laboratory shall within forty (40) days of its appointment determine the root cause of the non-conformity or Defect and its findings shall be conclusive and binding upon the parties; and 


  

	 	(d)	 all fees and expenses of the Laboratory shall be borne solely by the unsuccessful party. 



 

	23.4	 Remedy for Breach. The parties understand and agree that monetary damages may not be a sufficient remedy
for breach of this Agreement and that the injured party will be entitled to seek equitable relief, including injunction and specific performance, for any such breach. 



 

	24.	 MISCELLANEOUS 



 

	24.1	 Relationship of the Parties. For the purposes of this Agreement, each party shall be an independent
contractor and not an agent or employee of the other party. Neither party shall have authority or power to make any statements, representations or commitments of any kind, or to take any action which is binding on the other party, unless expressly
so authorized to do so by an instrument in writing signed by authorized representatives of such other party. 


  

	24.2	 Notices. Any notices which either party may be required or shall desire to give under this
Agreement shall be deemed to be duly given when in writing and delivered personally, mailed by registered mail or courier service to the party to whom notice is to be given, at the address specified below (which may be amended upon at least seven
(7) days prior written notice to the other party), or for any notices which either party may be required or shall desire to give under any Annex to this Agreement, shall be given at the address specified in such Annex. 



RECRO GAINESVILLE LLC 

1300 Gould Drive 
 Gainesville,
GA 30504 
 Attn: Scott Rizzo (General Manager) 

With a copy to: 
 Pepper
Hamilton LLC 
 3000 Two Logan Square 

Eighteenth and Arch Streets 

Philadelphia, PA 19103-2799 

Attn: Rachael Bushey 
 Attn:
Jennifer Porter 
 NOVARTIS PHARMA AG 

Lichtstrasse 35 
 CH-4056 Basel 
 Switzerland 

Attn: Head of External Supply Operations, Novartis Technical Operations  

Copy: Head of Legal Novartis Technical Operations 
  

	24.3	 No license. No license or right is granted by implication or otherwise with respect to any know-how, patent application or patent owned by NOVARTIS or any of its Affiliates or SUPPLIER or any of its Approved Subcontractors, except as and if specifically set forth herein. 



 

	24.4	 Annexes. All Annexes (and any amendments to such Annexes) and their enclosures form an integral
part of this Agreement and are incorporated herein by reference. 



  

			
	EXECUTION VERSION	  	Page 33 of 54















	24.5	 Order of Priority. In the event of any conflict, inconsistency or discrepancy between this
Agreement, the Annexes or the terms and conditions referenced or incorporated in this Agreement or the Appendices, the following order of priority shall apply: (i) the Quality Agreement (solely in respect of Quality Assurance, quality
management and compliance with the Applicable Standards), (ii) this Agreement, (iii) any Annexes, and (iv) individual Orders. 


  

	24.6	 Standard Terms. Except as expressly otherwise agreed in writing by the parties, the provisions of
this Agreement (including its Annexes) shall apply to any Order for the Product as well as any activity within the scope of this Agreement to the exclusion of any standard terms and conditions of either party, even if reference is made to such
standard terms and conditions by either party in any Order, or any other document. 


  

	24.7	 Force Majeure. Failure of any party to perform its obligations under this Agreement (other than
obligations to make any payments or of confidentiality) shall not subject such party to any liability or place them in breach of any term or condition of this Agreement to the other party if, and solely to the extent, such failure is caused by Force
Majeure. The corresponding obligations of the other party will be suspended to the same extent. “Force Majeure” shall mean any unanticipated event beyond a party’s (and/or its subcontractors’) reasonable control that could
not be avoided by due care of such non-performing party (and/or its subcontractors), including without limitation, acts of God, fire, explosion, flood, earthquake, drought, war, hostility, revolution, riot,
civil disturbance, national emergency, sabotage, or embargo; provided, however, that the party affected shall promptly notify the other party of the condition constituting Force Majeure as defined herein and shall exert commercially reasonable
efforts to eliminate, cure and overcome any such causes and to resume performance of its obligations with all possible speed. If a condition constituting Force Majeure as defined herein prevents, or would likely prevent, a party from performing its
obligations under this Agreement for more than ninety (90) days, the parties shall meet to negotiate a mutually satisfactory solution to the problem, if practicable, including the use of a third party to fulfil the obligations hereunder of the
party invoking Force Majeure at the expense of the party invoking Force Majeure. 


  

	24.8	 Entire Agreement. This Agreement (including the Annexes hereto) constitutes the entire agreement
between the parties related to the subject matter covered by this Agreement, and shall supersede and prevail over any other prior or contemporaneous arrangements regarding this subject matter, whether written or oral, and is binding upon the parties
hereto and their successors. No modification of this Agreement will be binding upon either party unless made in writing and signed by both parties. 


  

	24.9	 Assignment. Unless otherwise provided for herein, this Agreement and the rights and obligations
hereunder may not be assigned or transferred by either party hereto without the prior written consent of the other party, provided however, that NOVARTIS may assign this Agreement (in whole or in part) upon written notice to, but without the prior
approval of, SUPPLIER to: (i) an Affiliate of NOVARTIS; (ii) a third party in connection with the sale or disposal of all or part of the assets of NOVARTIS; or (iii) if NOVARTIS divests,
out-licenses or otherwise disposes of the Product or the business or assets relating to the Product. 


  

	24.10	 Delegation. NOVARTIS may delegate any of the activities under this Agreement to any of its
Affiliates, including without limitation Quality Assurance, regulatory ordering process, invoicing, artwork approval process, or supply chain related activities. In such case, NOVARTIS shall remain fully responsible for the performance of its
obligations under this Agreement by its Affiliate and SUPPLIER shall have no recourse against such Affiliate but shall address any claims or demands to NOVARTIS. 



  

			
	EXECUTION VERSION	  	Page 34 of 54















	24.11	 Severability. If any provision of this Agreement is held to be invalid or unenforceable, then the
offending provision (or the relevant part thereof) shall not render any other provision of this Agreement invalid or unenforceable, and the Agreement shall remain in full force and effect and shall be enforceable, and the invalid one shall be
replaced by a new provision which meets the original economic intent of the invalid provision as far as legally possible. 


  

	24.12	 Waiver. No delay or omission on the part of either party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof, nor shall any complete or partial waiver on the part of either party of any right, power or privilege hereunder, nor shall any single or partial exercise or any right, power or privilege
hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder. Any provision of this Agreement may be waived if, and only if, such waiver is in writing and signed by the party against whom
the waiver is to be effective. 


  

	24.13	 Survivorship. Any of the provisions of this Agreement, including the Annexes, that are expressed or
implied to survive the expiration or termination of this Agreement, shall remain in full force and effect. 


  

	24.14	 Execution. This Agreement may be executed in two or more counterparts and by facsimile or pdf electronic
signature, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts shall together constitute one and the same instrument. 



[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

			
	EXECUTION VERSION	  	Page 35 of 54














 Signed by the duly authorized representatives of each of the parties hereto as of the Effective Date. 

 

									
	NOVARTIS PHARMA AG	 		 	RECRO GAINESVILLE LLC
					
	By:	 	 /s/ Stefan Amberg
	 		 	By:	 	 /s/ M. Scott Rizzo

	Name:	 	Stefan Amberg	 		 	Name:	 	M. Scott Rizzo
	Title:	 	Head External Supply Organisation Europe	 		 	Title:	 	SVP & General Manager, Recro Gainesville, LLC
					
	By:	 	 /s/ Sarah Thomae
	 		 		 	
	Name:	 	Sarah Thomae	 		 		 	
	Title:	 	Senior Legal Counsel	 		 		 	
	
	NOVARTIS PHARMACEUTICALS CORPORATION (solely with respect to termination of the Development, License and Supply Agreement pursuant to Clause 2.9)
					
	By:	 	 /s/ John McKenna
	 		 		 	
	Name:	 	John McKenna	 		 		 	
	Title:	 	Chief Financial Officer, NPC	 		 		 	


  

			
	EXECUTION VERSION	  	Page 36 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 1 

PRODUCT & PRICING 

Ritalin LA 
  

																					
	 Pricing/M
	 	[***] capsules	 	 	[***] capsules	 	 	[***] capsules	 	 	[***] capsules	 	 	[***] capsules +	 
	 Ritalin LA [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Ritalin LA [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Ritalin LA [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Ritalin LA [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Ritalin LA [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 

 Focalin XR 
  

																	
	 Pricing/M
	 	[***] capsules	 	 	[***] capsules	 	 	[***] capsules	 	 	[***] capsules +	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 
	 Focalin XR [***](Bulk)
	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 	 	 	[***]	 


  

			
	EXECUTION VERSION	  	Page 37 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 2 

SAFETY STOCK REQUIREMENTS 
 [***]

 [***] 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

			
	EXECUTION VERSION	  	Page 38 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 3 
 Part
A – KEY PERFORMANCE INDICATORS 
 [***] 
 [***]

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

			
	EXECUTION VERSION	  	Page 39 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

 

					
	 KPI
	  	 Definition
	  	 Critical KPIs

(Yes/No)

	Number of Deviations	  	All deviations non-critical or critical decided/approved by Novartis QA in the reporting period.	  	
			
	Number of Deviations overdue	  	Number of all deviations considered by NOVARTIS to be overdue (at the agreed reporting period)	  	
			
	Complaint Rate	  	All complaints (justified and not justified, critical and non-critical) per units shipped externally (‘units shipped’). To be reported separately as a justified and not justified
complaints rate	  	
			
	Number of Complaints overdue	  	Definition imminent (during the agreed reporting period). In order to prevent double counting the Number has to be provided by the Organization (i.e. NOVARTIS or SUPPLIER) which investigates the complaint (not which received the
complaint)	  	
			
	Number of Complaints	  	All complaints non-critical or critical decided/approved by Novartis QA in the reporting period.	  	
			
	Number of Recalls	  	Total number of (decided) recalls presented as Year-to-date total	  	
			
	SDP (Supply Delivery Performance)	  	 SDP (formerly OTIF) measures the number of orders delivered and available to use (quality approved) within the time tolerance and within the
quantity tolerance.
  
 An order is considered a HIT if both data points (time and
quantity) are met.
 An order is considered a MISS if:

[***]
  

[***]
	  	Yes
			
	Savings as a percentage of spend last 12 months	  	Evaluated as (Price Previous Year-Price Current Year) * Quantity invoiced in Current Year. For multiple deliveries and invoices of the same item throughout the period, the weighted average price concept (weighted average price of
all supplier invoices during the current year compared with the weighted average price of the previous year) is normally applied.	  	


  

			
	EXECUTION VERSION	  	Page 40 of 54















					
	Collaboration (subjective measurement by NOVARTIS)	  	 Cooperation Mindset: This supplier has a generally cooperative spirit and approach to work with NOVARTIS, is willing to make
compromises when needed (i.e., no opportunistic behavior); there are concrete examples of joint collaboration initiatives with this supplier
  

1. Openness: This supplier is generally open to sharing data and information (e.g., on quality, cost, etc.) beyond traditional silos and is openly
communicating any internal problems (e.g., deviations)
  
 2. Improvement Drive:
This supplier is aspiring to truly bring their performance to the next level, going beyond requirements, across key functional performance areas (e.g., Quality, Service)
  

3. Responsiveness: This supplier always responds to any arising issues timely, both in terms of finding a short-term fix and a long-term solution;
communication with this supplier is generally easy and smooth (i.e., no/little need for follow-up, reminders, etc.)
  

4. Proactiveness: This supplier proactively identifies, flags, and resolves issues and pushes for the implementation of their resolution
	  	
			
	Innovation (subjective measurement by Novartis)	  	 1. Culture: This supplier is open to innovation, to new ways of working, and to change (whether it comes from Novartis or
elsewhere)
  
 2. Idea Generation & Implementation: This
supplier proactively generates improvement ideas themselves, has drive and perseverance to implement them, is willing to invest in innovation and take risks
  

3. Track Record: There are concrete examples of key innovation or co-development projects with this supplier
over the last year
	  	


  

			
	EXECUTION VERSION	  	Page 41 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

Part B - KPI Targets & Scoring Mechanism 
  

													
	 	  	 	  	Scoring mechanism	  	 	  	 
	 Area
	  	 KPI
	  	Performance Points to be
allocated	  	Performance	  	Score
	 	  	 	  	1	  	3	  	5	  	 	  	 
	 Quality

([***]%)
	  	No. of deviations overdue	  	[***]	  	[***]	  	[***]	  		  	
	  	APR/ PQR overdue	  	[***]	  	[***]	  	[***]	  		  	
	  	No. of complaints overdue	  	[***]	  	[***]	  	[***]	  		  	
	  	Complaint rate	  	[***]	  	[***]	  	[***]	  		  	
	  	No. of recalls	  	[***]	  	[***]	  	[***]	  		  	
	  	Quality overall	  		  		  		  		  	
							
	 Service

([***]%)
	  	 SDP
 Service overall
	  	[***]	  	[***]	  	[***]	  		  	
							
	 Cost

([***]%)
	  	 Savings as share of spend, last 18 months

Cost overall
	  	[***]	  	[***]	  	[***]	  		  	
							
	 Collaboration

([***]%)
	  	 Collaboration score overall by SRT

Collaboration overall
	  	[***]	  	[***]	  	[***]	  		  	
							
	 Innovation

([***]%)
	  	 Innovation score overall by SRT

Innovation overall
	  	[***]	  	[***]	  	[***]	  		  	
							
	 Overall score
	  		  		  		  		  		  	


  

			
	EXECUTION VERSION	  	Page 42 of 54














 ANNEX 4 

RELATIONSHIP MANAGEMENT 

1.    Supplier Representatives. SUPPLIER shall establish a customer interface team headed by a dedicated key account manager as
primary point of contact to NOVARTIS. 
 2.    Joint Supply Team. The parties shall establish a joint supply team (the
“Joint Supply Team”) which shall be composed of an equal number of employees from NOVARTIS’ and SUPPLIER’s operational team responsible for performance under this Agreement. Either Party may replace any or all of
its representatives at any time by written or electronic notice to the other Party. 
 3.    Meetings. The Joint Supply Team
shall meet at least once per calendar month, or as otherwise agreed by the Joint Supply Team. Meetings shall occur by teleconference, videoconference or in person. 

4.    Responsibilities. The Joint Supply Team shall supervise and coordinate the collaboration of the parties under this Agreement,
including technical aspects, logistics and planning, Quality Assurance, quality control, regulatory aspects and compliance and shall serve as a point of escalation for all issues that arise during the performance of this Agreement. In particular,
the Joint Supply Team shall: 
  

	(a)	 regularly discuss projected demand requirements and supply plans (S&OP) for the Products;



  

	(b)	 discuss any proposed Manufacturing changes; 



 

	(c)	 review and discuss a mutual continuous improvement and competitive best practices strategy;



  

	(d)	 review and discuss the KPIs; and 



 

	(e)	 carry out any other duties that are allocated to it under this Agreement. 



The Joint Supply Team shall not have any authority to modify the terms of this Agreement. 

Minutes. Joint Supply Team meetings shall be chaired by a Joint Supply Team member of NOVARTIS. The chair shall be responsible to keep reasonably
detailed minutes of the relevant meetings. Minutes of Joint Supply Team meetings shall be sent to all Joint Supply Team members, for review and approval within ten (10) business days. Minutes shall be deemed approved unless any Joint Supply
Team member objects to the accuracy of such minutes within ten (10) business days of receipt. 

  

			
	EXECUTION VERSION	  	Page 43 of 54














 ANNEX 5 

TRADING SERVICES PROCEDURE 
 (As
attached, immediately following this page, and the remainder of this page is left blank intentionally.) 

  

			
	EXECUTION VERSION	  	Page 44 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

[***] [Twenty-four pages omitted in their entirety] 

  













 ANNEX 6 

QUALITY AGREEMENT 
 (As attached,
immediately following this page, and the remainder of this page is left blank intentionally.) 

  

			
	EXECUTION VERSION	  	Page 45 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

[***] [Eighty-three pages omitted in their entirety] 

  













 ANNEX 7 

ADDITIONAL HSE REQUIREMENTS 

During the Term, SUPPLIER shall comply with the additional HSE requirements set forth in this ANNEX and shall procure that its Approved Subcontractors and
suppliers similarly comply with each of these additional HSE requirements, in each case solely as it relates to the Product and/or any Novartis procedures applicable thereto. 
  


	1.	 HSE Audit Rights 



 

	 	a.	 SUPPLIER shall establish and maintain a HSE audit program for its Approved Subcontractors, its suppliers and
its supply chain generally in order to ensure SUPPLIER’s compliance with the HSE Requirements. Upon request, SUPPLIER shall provide any audit reports related thereto to NOVARTIS. 



 

	 	b.	 SUPPLIER shall (and shall cause its Approved Subcontractors and suppliers to) grant NOVARTIS, its Affiliates
and its designated representatives access to the Facility and to any other facilities where any activities falling within the scope of this Agreement are being performed. This includes access to equipment, as well as to any documents, records,
reports, data, procedures, regulatory submissions, and any other information required to be maintained under the HSE Requirements, for the purposes of auditing compliance with the HSE Requirements. 



 

	 	c.	 SUPPLIER shall enable (and shall cause its Approved Subcontractors and suppliers to enable) NOVARTIS, its
Affiliates and designated representatives to take sufficient quantities of samples in order to reasonably verify compliance with the HSE Requirements. 


  

	2.	 HSE Training. SUPPLIER shall ensure that any persons engaged in activities falling within the scope of
this Agreement have adequate HSE training, including training in handling hazardous materials (as defined under Applicable Standards). 


  

	3.	 Incident Reporting. SUPPLIER shall immediately report to NOVARTIS any serious HSE incident (including
fatalities, loss of body parts, spills beyond facility boundaries, etc.) representing a failure to comply with Applicable Standards relating to HSE as it relates to the Product and/or any Novartis procedures applicable thereto. This includes,
without limitation, any incident resulting in involvement of Regulatory Authorities or other governmental authorities or any HSE related incidents with actual or potential impact on supply continuity. 



 

	4.	 Contact information. For each Facility or location where any of the activities falling within the scope
of this Agreement are being performed, SUPPLIER shall communicate to NOVARTIS the name and contact information (including telephone and e-mail address) of at least one responsible and qualified contact person
for HSE related topics. 


  

	5.	 HSE Management System. SUPPLIER shall, for each Facility or location where any activities falling within
the scope of this Agreement are being performed, ensure that HSE management systems are in place and maintained throughout the Term in accordance with Applicable Standards as well as with the following: 



 

	 	(a)	 EMAS 



  

			
	EXECUTION VERSION	  	Page 46 of 54















	 	(b)	 OHSAS 18001 



If, on the Effective Date, SUPPLIER does not have a HSE management system in place which meets the above criteria, then SUPPLIER shall promptly
so notify NOVARTIS, provided, however, that on such date, SUPPLIER shall have in place and maintain throughout the Term the following minimum elements: 
  

	 	(a)	 HSE policy; 


  

	 	(b)	 adequate documentation on the effects of any Facility, services and activities on the environment;



  

	 	(c)	 HSE risk assessment(s); and 



 

	 	(d)	 general and detailed HSE targets and HSE requirements for SUPPLIER’s own suppliers. 




  

			
	EXECUTION VERSION	  	Page 47 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 8 
 Toll
Materials 
  

	 	A.	 Yield Loss Rates and Reimbursement Value 



 

									
	 Toll Material
	  	Toll Material Yield Loss
Rate	 	  	Toll Material Reimbursement
Value	 
	 [***]
	  	 	[***] percent ([***]%)	 	  	$	[***]/KG	 
		  				  	  
	  
	 
	 [***]
	  				  	$	[***]/KG	 
		  				  	  
	  
	 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

			
	EXECUTION VERSION	  	Page 48 of 54














 ANNEX 8 

 

	 	B.	 Stock Count Procedure for Toll Materials 



 

											
	 Reporting SUPPLIER    
	 	 	  	     Reporting    

    Month:    
	  	
                   
         
 
	  	     Date:    
	  	
                   
         


  

	1.	 Toll Materials (free of charge Toll Materials) 



 

																													
	 Product Name
	  	Novartis
Product
Code	 	  	Unit
of
Measure	 	  	Quantity
on Stock
(a)	 	  	Quantity
Work in
Progress
(WIP)
(b)	 	  	Quantity
of Toll
Materials
contained
in finished
Products,
ex 
Section
2
(c)	 	  	Total Stock
(a)+(b)+(c)	 	  	Last order number received
from Novartis,
batch number and delivery
date	 
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			


  

			
	EXECUTION VERSION	  	Page 49 of 54















	2.	 Finished Products 



 

																													
	 Product Name
	  	Novartis
Product
Code	 	  	Unit
of
Measure	 	  	Quantity
on Stock	 	  	Last lot
number
of
shipped
finished
Product	 	  	Novartis
Product
Code of
starting
material	 	  	UoM	 	  	Quantity of starting
material,
to be reported in
Section 1 (c)	 
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			

  

	3.	 Inventory differences, write-offs and extraordinary consumption of Toll Materials (in quantity of free of
charge Toll Material) 


  

																									
	 Product Name
	  	Novartis
Product
Code	 	  	Unit
of
Measure	 	  	Quantities	 	  	Reason / Explanation please
indicate batch number of
finished product or 
of free
of charge Toll Material	 
	  	Write-offs	 	  	Slow/Non-Movers	 	  	Extra-
ordinary
consum-
ption of Toll
Materials	 
		  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			
		  				  				  				  				  				  			

  

	4.	 Reconciliation Statement of physical count result and quantities reported to Novartis (at least once per
year) 


 SUPPLIER hereby confirms that the result of the physical stock count that has been carried out in accordance to local law
and generally accepted accounting rules correspond to the quantities reported under this report. NOVARTIS may request a stock take, attend to it or ask for more supporting documentation. 

 

			
	Date of physical count (or indication of inventory method)	 	  

		
	Date of next physical count	 	  

		
	Signature	 	  

		
		 	  



  

			
	EXECUTION VERSION	  	Page 50 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 9 
 ALKERMES PATENT
RIGHTS 
  

																																	
	 [***] 
	  	[***] 	 	  	[***] 	 	  	[***] 	 	  	[***] 	 	  	[***] 	 	  	[***] 	 	  	[***] 	 	  	[***] 	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
									
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 


  

			
	EXECUTION VERSION	  	Page 51 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 10 
 RECRO PATENT
RIGHTS 
  

																																	
	 [***]
	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  				  				  	 	[***]	 	  	 	[***]	 


  

			
	EXECUTION VERSION	  	Page 52 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

ANNEX 11 
 LIST OF OPEN
ORDERS 
 SHIPMENTS AND INVOICES RECEIVED AS OF FEBRUARY 4, 2019 
  

																					
	 Description
	  	PO	 	  	Quantity	 	  	Posting Date	 	  	Invoice $	 	  	Invoice No.	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 

 PURCHASE ORDERS PLACED IN 2018 AND DELIVERING IN 2019 

 

																							
	 Sales

Document
	  	Purchase
Order	 	  	Materials	 	  	 Description
	  	Batch	 	  	Order
Quantity	 	  	Delivery
Date	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 


  

			
	EXECUTION VERSION	  	Page 53 of 54














 [***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. 
  

																					
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  				  	 	[***]	 	  	[***]
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	
	 [***]
	  	 	[***]	 	  	 	[***]	 	  	[***]	  	 	[***]	 	  	 	[***]	 	  	


  

			
	EXECUTION VERSION	  	Page 54 of 54